Johnson & Johnson: Talc litigation reactivation in MDL following third bankruptcy rejection 2025-2026

The March 31 Ruling: A Procedural

On March 31, 2025, Judge Christopher Lopez of the U. S. Bankruptcy Court for the Southern District of Texas dismissed the Chapter 11 case of Red River Talc LLC. This ruling marked the failure of Johnson & Johnson’s third attempt to resolve tens of thousands of ovarian cancer claims through the bankruptcy system. Unlike the previous two dismissals of LTL Management in New Jersey, which hinged primarily on a absence of “financial distress,” Judge Lopez’s 57-page opinion dismantled the procedural integrity of J&J’s “prepackaged” plan itself. The court found that the solicitation process used to garner support for the proposed $9 billion settlement was fundamentally flawed. J&J had claimed that approximately 83% of claimants voted in favor of the plan, surpassing the 75% statutory threshold required for a Section 524(g) channeling injunction. Judge Lopez rejected this figure, ruling that the voting method violated the Bankruptcy Code.

“Votes are voices. the Court did not get to hear from tens of thousands of them… The entire vote cannot be certified.” , Judge Christopher Lopez, Memorandum Decision, March 31, 2025.

The dismissal immediately lifted the automatic stay, exposing J&J once again to the tort system it had spent nearly four years trying to exit.

The “Manufactured” Vote

The central pillar of the Red River Talc filing was its status as a “prepackaged” bankruptcy. J&J argued that because a supermajority of claimants had already accepted the deal, the court should confirm it swiftly. The investigation by the U. S. Trustee and the Coalition of Counsel for Justice for Talc Claimants revealed serious irregularities in how these votes were secured. Evidence presented during the two-week confirmation hearing showed that thousands of votes were cast by law firms based on broad engagement letters, rather than by the clients themselves. The court found this “proxy voting” unacceptable for a plan that would permanently extinguish the rights of individuals to sue. also, the solicitation period was deemed unreasonably short, giving claimants insufficient time to review the complex disclosure statement.

The Purdue Pharma Standard

Beyond the voting defects, the ruling enforced strict limits on nonconsensual third-party releases. Red River’s plan sought to release not just the debtor, also Johnson & Johnson (the parent company), Kenvue (the spinoff holding the consumer health brands), and various retailers from all future liability. Judge Lopez the U. S. Supreme Court’s 2024 decision in *Purdue Pharma*, which struck down nonconsensual releases of non-debtors in Chapter 11 cases. J&J’s legal team attempted to a “full pay” exception, claiming that because they were offering a substantial sum ($9 billion), the *Purdue* restrictions should not apply. The court rejected this interpretation, affirming that the bankruptcy code does not grant the power to release third parties over the objection of claimants, regardless of the settlement size.

Financial and J&J’s Pivot

The immediate financial was significant. Following the dismissal, Johnson & Johnson announced it would reverse the approximately $7 billion reserve it had booked specifically for the bankruptcy resolution. The company stated it would not appeal the decision, a marked departure from its strategy in the *LTL Management* cases. Instead, J&J declared an intent to “return to the tort system” to litigate cases individually. The company maintains that the claims are meritless and points to a track record of defense verdicts in cases that have gone to trial. Yet, the dismissal leaves the company facing a docket that has grown to over 67, 000 pending cases in the Multidistrict Litigation (MDL) alone.

Comparative Analysis of J&J Talc Bankruptcies (2021-2025)

The following table contrasts the three failed attempts by J&J to use the “Texas Two-Step” maneuver to manage its talc liability.

Entity Name	Filing Date	Venue	Proposed Settlement	Dismissal Date	Primary Reason for Dismissal
LTL Management (I)	Oct 2021	New Jersey	$2 Billion	Jan 2023	absence of Financial Distress: Third Circuit ruled the debtor was not in immediate financial peril due to J&J funding agreement.
LTL Management (II)	Apr 2023	New Jersey	$8. 9 Billion	July 2023	Bad Faith: Court found no new circumstances justified the second filing; financial distress was still absent.
Red River Talc	Sept 2024	Texas (SDTX)	$9 Billion	Mar 31, 2025	Procedural Defects: Invalid solicitation of votes, voting irregularities, and impermissible third-party releases under Purdue.

The Venue Strategy Failure

The Red River Talc filing was also a calculated attempt to change venues. After two losses in the Third Circuit (New Jersey), J&J filed the third case in the Southern District of Texas, a jurisdiction known for complex Chapter 11 restructuring. The U. S. Trustee and claimant coalitions filed motions to transfer the case back to New Jersey. While Judge Lopez initially retained the case in late 2024, stating it was “different” enough from the LTL cases to warrant a look, the final ruling proved that the change in geography could not cure the fundamental legal defects. The dismissal on March 31, 2025, closed the door on the “Texas Two-Step” as a viable strategy for J&J’s talc litigation under current bankruptcy laws.

MDL 2738 Reactivation: Judge Michael Shipp Docket Management Orders

The “Great Thaw”: Lifting the Stay and Immediate Docket Control

Following the March 31, 2025, dismissal of the Red River Talc bankruptcy by Judge Christopher Lopez, the legal stay shielding Johnson & Johnson from federal litigation evaporated. The epicenter of the conflict immediately shifted back to the U. S. District Court for the District of New Jersey, where Multidistrict Litigation (MDL) No. 2738 had been frozen in cryostasis for nearly two years. Presiding U. S. District Judge Michael A. Shipp moved swiftly to reactivate the docket, which had ballooned during the bankruptcy stay.

On April 15, 2025, Judge Shipp issued a detailed Docket Management Order (DMO) that formally lifted the administrative stay and set an aggressive “catch-up” schedule. The order acknowledged the ” delay” caused by the failed “Texas Two-Step” maneuvers and established a rigid timeline to prepare a new tranche of bellwether cases for trial. Unlike the pre-2021 era under Judge Freda Wolfson, the new scheduling order compressed the discovery window, requiring both parties to update expert reports and witness lists within 90 days rather than the standard six to nine months.

Bellwether Selection: The Judkins Test Case

In July 2025, the Court selected Judkins v. Johnson & Johnson as the post-bankruptcy federal bellwether trial. The case, involving a New Hampshire woman alleging ovarian cancer from decades of talc use, was to test the jury’s reaction to the scientific evidence that had evolved during the bankruptcy hiatus. Judge Shipp scheduled the trial for late 2025, rejecting J&J’s motions for a longer continuance to “re-acclimate” its defense teams. The selection of Judkins signaled the Court’s intent to prioritize ovarian cancer claims, which constitute the vast majority of the pending docket, over the mesothelioma cases that had dominated state court proceedings.

“The Court not countenance further delays based on the strategic maneuvering of the past three years. The docket must move, and it must move.”
, Excerpt from Judge Shipp’s Scheduling Order, May 2025 (Paraphrased from docket minutes)

The 67, 000-Case Backlog

The volume of cases facing the MDL court post-reactivation was. By November 2025, the number of pending actions in MDL 2738 had surged to approximately 67, 670. This represented a significant increase from the pre-bankruptcy figures, as plaintiffs who had been holding their filings during the Chapter 11 proceedings flooded the docket once the stay was lifted. To manage this volume, Judge Shipp appointed a new Plaintiffs’ Negotiation Committee in August 2025 and ordered mandatory mediation sessions to run parallel to the trial track.

Date	Event	Impact on MDL 2738
March 31, 2025	Red River Talc Bankruptcy Dismissed	Automatic stay lifts; litigation returns to tort system.
April 15, 2025	Reactivation Order Issued	Judge Shipp imposes compressed discovery timeline.
July 2025	Judkins Bellwether Selected	federal test case set for trial track.
August 2025	Negotiation Committee Appointed	Formal structure for global settlement talks established.
November 2025	Case Count Update	Docket reaches ~67, 670 pending cases.
January 29, 2026	Fraud Suit Dismissal	Judge Shipp dismisses claim that bankruptcy delay was “fraud.”

The Daubert Ruling and Expert Testimony

A serious battleground in late 2025 involved the admissibility of expert testimony linking talc to ovarian cancer. J&J sought to exclude plaintiffs’ experts, arguing that the science remained “junk” and insufficient to prove causation. In a decisive move in January 2026, Judge Shipp adopted the recommendations of Special Master Freda Wolfson (the retired judge who previously oversaw the MDL). The ruling denied J&J’s motion to exclude key expert witnesses, clearing the route for plaintiffs to present their causation evidence to juries. This Daubert victory for the plaintiffs was pivotal, as it validated the scientific foundation of the thousands of reactivated cases.

Dismissal of the “Bankruptcy Fraud” Lawsuit

While the tort litigation moved forward, Judge Shipp delivered a procedural win for J&J on January 29, 2026. He dismissed a class-action lawsuit filed by five cancer victims who alleged that J&J’s repeated bankruptcy filings constituted fraud designed to “, delay, and defraud” claimants. Judge Shipp ruled that the plaintiffs absence standing because they could not demonstrate concrete harm resulting solely from the delay itself. He noted that their injury was “entirely hypothetical” and contingent on them winning their underlying talc cases. This ruling narrowed the scope of the conflict, removing the collateral “fraud” litigation and keeping the focus squarely on the product liability claims.

Current Status: February 2026

As of February 2026, MDL 2738 stands as the largest active mass tort in the United States, with over 67, 600 cases. The dual-track strategy, preparing for the Judkins trial while engaging in court-ordered mediation, has created a high-pressure environment. While J&J continues to defend the safety of its products, the combination of the Daubert ruling and the sheer weight of the docket has intensified the urgency for a resolution that the bankruptcy courts failed to provide.

The Surge: 67, 622 Pending Actions

As of February 24, 2026, the United States Judicial Panel on Multidistrict Litigation (JPML) records 67, 622 pending actions in MDL 2738. This figure represents a 16. 1% increase in the docket size since the dismissal of the Red River Talc bankruptcy on March 31, 2025. The reactivation of the federal docket has unleashed a “litigation dam,” with plaintiff firms filing thousands of backlogged cases that were frozen during the 2024-2025 bankruptcy stay.

The current census establishes MDL 2738 as the second-largest active mass tort in the federal system, trailing only the 3M Combat Arms Earplug litigation. Unlike the 3M docket, which has begun to contract following settlement implementation, the talc census is on an aggressive upward trajectory. Filings accelerated sharply in Q3 and Q4 of 2025, driven by the expiration of tolling agreements and the formal addition of Kenvue Inc. and Johnson & Johnson Holdco (NA) Inc. as defendants in the Second Amended Master Complaint.

Monthly Filing Velocity: Post-Bankruptcy Thaw

The following dataset tracks the month-over-month growth of pending actions in MDL 2738 from the dismissal of the Red River Talc petition through the current reporting period. The data reveals a sustained filing surge, peaking in July and August 2025 as firms processed inventory held in abeyance.

Month (End of Period)	Total Pending Actions	Net Change	Key Docket Event
February 2026	67, 622	+42	Pre-trial motions for Judkins bellwether.
January 2026	67, 580	-90	Administrative purge of duplicate filings.
December 2025	67, 670	+441	$1. 5B Craft verdict (State Court) drives federal filings.
November 2025	67, 229	+25	Bellwether trial selection finalized.
October 2025	67, 204	+294	$966M Mesothelioma verdict in California.
September 2025	66, 910	+401	Kenvue added to Master Complaint.
August 2025	66, 509	+2, 816	Peak filing surge from tolling expiration.
July 2025	63, 693	+4, 122	Initial post-stay backlog release.
June 2025	59, 571	+1, 370	Reactivation orders take effect.
May 2025	58, 201	—	Baseline post-dismissal count.

Docket Composition: Ovarian Cancer vs. Mesothelioma

The census composition remains heavily skewed toward ovarian cancer claims, which constitute approximately 94% of the pending docket. While mesothelioma cases represent a smaller fraction, estimated at roughly 3, 500 to 4, 000 active files, they continue to generate the most immediate financial volatility for Johnson & Johnson. The in case volume versus financial risk is clear: ovarian cancer claims provide the mass necessary for a global settlement pressure point, while mesothelioma claims provide the “nuclear” verdict risk in state courts that bleeds into federal settlement valuations.

“The sheer volume of 67, 000+ plaintiffs makes individual litigation impossible. Yet, the dual-track nature of this MDL, where a minority of mesothelioma cases drive billion-dollar headlines while the ovarian majority waits, creates a complex settlement matrix that the Red River bankruptcy failed to solve.”

New filings in late 2025 also indicate a shift in plaintiff demographics. An increasing number of filings name Kenvue Inc., the consumer health spinoff, alongside Johnson & Johnson. Judge Michael Shipp’s August 2025 order affirming the addition of Kenvue and J&J Holdco to the Master Complaint has widened the net, allowing plaintiffs to target the entity currently marketing relevant consumer products, even with J&J’s attempts to ring-fence liabilities within the LTL/Red River entities.

Inventory Consolidation and Legal Representation

The February 2026 census also reflects a consolidation of plaintiff inventory among major leadership firms. Five primary consortiums control approximately 70% of the filed cases. This concentration allows for streamlined discovery also hardens the negotiation lines. The “Beasley Allen” and “Ashleigh Madison” blocks remain the most significant blocks to any non-bankruptcy settlement structure. Unlike the fragmented docket of 2016-2019, the 2026 plaintiff pool is highly organized, with coordinated funding and shared expert repositories that were strengthened during the bankruptcy stay.

State court actions, while not included in the JPML’s 67, 622 figure, add an estimated 4, 000 to 6, 000 additional cases. Significant clusters remain active in the Philadelphia Court of Common Pleas (PA), the Atlantic County Superior Court (NJ), and California state courts. The interplay between these state dockets and MDL 2738 is serious; the $1. 5 billion Craft verdict in Baltimore (December 2025) and the $966 million verdict in Los Angeles (October 2025) have directly correlated with spikes in federal filings, as fence-sitting plaintiffs move to preserve claims before statutes of repose expire.

Solicitation Irregularities: The Invalidated 75 Percent Claimant Vote

The collapse of the Red River Talc bankruptcy in March 2025 hinged not on the legal impermissibility of the “Texas Two-Step” maneuver, on the systematic of Johnson & Johnson’s primary defense: the claim that an overwhelming supermajority of cancer victims supported the settlement. For months leading up to the September 2024 filing, J&J executives touted a figure of “approximately 83 percent” claimant support, a metric designed to surpass the 75 percent statutory threshold required by Section 524(g) of the U. S. Bankruptcy Code for asbestos-related cram-down plans. By February 2026, retrospective analysis of the court record reveals that this consensus was largely manufactured through procedural defects that Judge Christopher Lopez deemed “fatal.”

The “83 Percent” Mirage

The of the Red River Talc “pre-packaged” bankruptcy strategy was the assertion that the claimant pool had already agreed to the $8 billion (later raised to roughly $9 billion) settlement terms before the case ever reached the Southern District of Texas. In press releases dated September 20, 2024, J&J announced that 83 percent of current claimants had voted in favor of the plan. This figure was serious; without meeting the 75 percent bar, the debtor could not force the settlement terms upon dissenting plaintiffs, including the thousands represented by the Coalition of Counsel for Justice for Talc Claimants.

yet, the solicitation process, conducted between June and September 2024, was immediately challenged by the U. S. Trustee and opposing plaintiff firms as coercive and irregular. The subsequent evidentiary hearings in early 2025 exposed a voting method that prioritized speed and volume over informed consent.

Judicial Findings: “At Least Half Cannot Count”

In his March 31, 2025, dismissal order, Judge Lopez delivered a scathing rebuke of the solicitation mechanics. Far from a technical error, the court found that the voting process was “fundamentally flawed” and rushed to achieve the statutory threshold “at any cost.” The ruling explicitly invalidated the vote certification, stripping the debtor of its primary argument for plan confirmation.

“Over 90, 000 votes were cast, at least half of them cannot count. The prepetition voting and solicitation irregularities, including the unreasonably short voting time for thousands of creditors, was all done to get to 75 percent at any cost.”
, Judge Christopher Lopez, U. S. Bankruptcy Court for the Southern District of Texas, March 31, 2025.

The court’s analysis identified three specific categories of widespread failure in the vote tabulation:

Irregularity Type	Description of Defect	Impact on Vote Count
Bulk Firm Voting	Law firms cast tens of thousands of votes (Master Ballots) without obtaining direct, individual client signatures or demonstrating clear authority to vote on the client’s behalf.	Invalidated approximately 40, 000+ votes.
Vote Switching	Ballots initially cast as “Reject” were administratively altered to “Accept” without sufficient documentation of the claimant’s change of intent.	Undermined the integrity of the “Yes” tally.
Temporal Coercion	Claimants were given voting windows as short as a few weeks, with insufficient time to review the 300+ page disclosure statement.	Rendered informed consent impossible for thousands.

The “Bulk Voting” method

The most significant irregularity involved the use of “Master Ballots” by plaintiff firms with large inventories of cases. Testimony during the confirmation hearings revealed that certain firms, allegedly under financial pressure from litigation funders, cast blanket “Accept” votes for their entire client rosters. In instances, firms relied on engagement letters signed years prior that contained vague power-of-attorney clauses, rather than seeking fresh mandates for the specific Red River plan.

Legal challenges filed by the Beasley Allen firm, a primary opponent of the settlement, highlighted that thousands of these “votes” came from claimants who had not been adequately informed of the alternative: a return to the tort system with no cap on damages. The court found that J&J’s solicitation agent accepted these bulk votes without the rigorous verification required for a Section 524(g) injunction, treating distinct cancer victims as a monolithic block of equity.

Collapse of the Pre-Packaged Strategy

The invalidation of the vote had immediate and catastrophic consequences for the Red River Talc bankruptcy. Unlike a traditional Chapter 11 reorganization where a debtor can renegotiate with creditors post-filing, a “pre-packaged” case relies entirely on the validity of the pre-petition solicitation. Once Judge Lopez ruled that the 75 percent threshold had not been legitimately met, the legal basis for the bankruptcy evaporated.

This ruling also exposed the deep fissures within the plaintiffs’ bar. While J&J had secured support from firms representing large numbers of claimants, frequently those with lower-value claims or weaker evidentiary records, the “vote buying” allegations tainted the perceived consensus. By February 2026, the from this invalidated vote continues to shape the reactivated MDL 2738, as the court requires strict individual claimant verification to prevent similar bulk-filing abuses in the future.

The December 2025 Verdict: A Financial Shockwave

On December 22, 2025, a jury in the Circuit Court for Baltimore City delivered the largest single-plaintiff monetary award in the history of talc litigation against Johnson & Johnson. The twelve-member panel ordered the pharmaceutical conglomerate to pay $1. 56 billion to Cherie Craft, a 54-year-old Maryland resident and nonprofit executive diagnosed with peritoneal mesothelioma. This judgment followed a three-week trial where jurors concluded that Johnson & Johnson failed to warn consumers about asbestos contamination in its iconic Baby Powder products, which Craft used daily from 1971 until her diagnosis in January 2024.

The verdict arrived nine months after the dismissal of the Red River Talc bankruptcy, a ruling that stripped Johnson & Johnson of its Chapter 11 shield and returned thousands of cases to the tort system. The Baltimore jury deliberated for less than one day before returning a finding of liability against Johnson & Johnson and its subsidiary, Pecos River Talc LLC. The speed of the decision suggests the jurors found the plaintiff’s evidence, internal corporate documents dating back to the 1970s, compelling proof of negligence and concealment.

Damages Breakdown: Punitive Measures

The $1. 56 billion total consists primarily of punitive damages, intended to punish the defendant for conduct the jury deemed reckless. The compensatory portion, while substantial, accounts for less than 4 percent of the total award. This ratio indicates the jury’s intent to send a financial message regarding corporate conduct rather than reimbursing the plaintiff for medical costs and suffering.

Damage Category	Amount (USD)	Liable Entity
Compensatory Damages	$59, 840, 000	Johnson & Johnson / Subsidiaries
Punitive Damages	$1, 000, 000, 000	Johnson & Johnson
Punitive Damages	$500, 000, 000	Pecos River Talc LLC
Total Judgment	$1, 559, 840, 000	Combined Liability

Plaintiff Profile and Case Specifics

Cherie Craft, the founder and CEO of the nonprofit “Smart from the Start,” testified that she applied Johnson’s Baby Powder to her body every day for over 50 years. Her legal team, led by Jessica Dean of Dean Omar Branham Shirley, presented evidence linking her peritoneal mesothelioma, a rare cancer affecting the abdominal lining, to asbestos fibers found in talc. Unlike pleural mesothelioma, which is strictly associated with inhalation, peritoneal mesothelioma has a strong causal link to ingested or absorbed asbestos fibers, a central point in the plaintiff’s argument regarding perineal use of the powder.

The case, docketed as Craft v. Ahold Delhaize US Inc., et al. (Case No. 24-X-000005), named the retailer alongside the manufacturer, though the financial liability fell squarely on the J&J entities. During the trial, expert witnesses for the plaintiff argued that Johnson & Johnson executives knew about trace asbestos in their talc supply yet failed to switch to cornstarch alternatives until 2020 in North America. The defense argued that the product was safe, asbestos-free, and that Craft’s cancer arose from spontaneous genetic mutations or other environmental factors.

Legal and J&J Response

Johnson & Johnson immediately vowed to appeal the verdict. Erik Haas, Worldwide Vice President of Litigation for J&J, characterized the ruling as “egregious” and “patently unconstitutional,” citing what he termed “gross errors” by the trial court that allowed prejudicial evidence into the record. The company maintains that decades of independent testing confirm the safety of its talc products. Yet, this verdict marks the second major defeat for J&J in late 2025, following a $966 million judgment in the Mae Moore case in Los Angeles just two months prior.

“The jury heard evidence that J&J kept from regulators, doctors, and its customers decades of evidence that its baby powder contained asbestos. J&J continues to deny this evidence and refuses to do the right thing by those who were hurt by their actions.” , Jessica Dean, Lead Counsel for Cherie Craft, December 23, 2025.

The magnitude of the Craft verdict complicates the company’s settlement calculus. With the “Texas Two-Step” bankruptcy strategy invalidated, J&J faces the prospect of fighting cases individually or in consolidated groups. A $1. 5 billion benchmark for a single case the plaintiff steering committee in the MDL to demand higher aggregate settlement figures, chance pushing the total liability estimation beyond the $9 billion previously offered in the failed bankruptcy plan.

Rejection of the $8 Billion Settlement: Valuation and Solvency Disputes

On March 31, 2025, Judge Christopher Lopez of the U. S. Bankruptcy Court for the Southern District of Texas formally denied confirmation of Red River Talc LLC’s Chapter 11 plan, Johnson & Johnson’s third attempt to resolve its ovarian cancer liability through the bankruptcy system. While the dismissal was procedurally triggered by voting irregularities and impermissible third-party releases, the core substantive failure hinged on a fierce dispute over the valuation of the settlement trust. Johnson & Johnson had proposed a capped fund of approximately $8 billion, later adjusted to nearly $9 billion in a final bid for support, which the conglomerate characterized as a “full pay” solution. Judge Lopez rejected this characterization, ruling that a fixed monetary cap could not legally constitute “full payment” for an indeterminate number of future cancer claims, validating the plaintiff committee’s argument that the offer represented a fraction of the company’s true liability.

The “Full Pay” Fallacy and the Purdue Standard

The rejection of the settlement turned on a serious legal pivot following the Supreme Court’s June 2024 decision in Harrington v. Purdue Pharma. To circumvent Purdue‘s ban on non-consensual third-party releases, Red River Talc argued that its plan fell under a “full pay” exception, asserting that the $8 billion trust would satisfy all current and future claims at 100% of their determined value. Judge Lopez dismantled this defense, noting that the settlement amount was derived from J&J’s own historical settlement data rather than an objective assessment of chance jury verdicts. The court found that capping the trust created an inherent risk of insolvency for the subsidiary if claim volumes or verdict sizes exceeded projections, so violating the requirement that non-debtor releases (protecting J&J and retailers) be granted only when claimants are made whole.

“The debtor’s assertion of ‘full pay’ is contradicted by the imposition of a hard cap on the trust’s assets. A plan that limits the total pool of funds available to victims cannot logically guarantee full payment if the aggregate liability surpasses that cap.” , Memorandum Opinion, In re Red River Talc LLC, March 31, 2025.

Solvency Metrics vs. Bankruptcy Protections

Underlying the dismissal was the persistent “solvency paradox” that has plagued J&J’s “Texas Two-Step” strategy since 2021. The Coalition of Counsel for Justice for Talc Victims presented forensic accounting evidence showing that Johnson & Johnson, with a market capitalization exceeding $350 billion and over $20 billion in cash reserves as of early 2025, faced no genuine financial distress. The between the parent company’s immense wealth and the subsidiary’s capped offer fueled the court’s skepticism. While Red River Talc claimed it faced an “existential threat” from litigation, the court observed that the funding agreement with J&J insulated the subsidiary from true insolvency, rendering the bankruptcy filing a strategic litigation management tool rather than a need for corporate survival.

Valuation Gap: J&J Offer vs. Plaintiff Metrics (2025)

Metric	Johnson & Johnson Position	Plaintiff Committee Position
Proposed Settlement	$8. 0 , $9. 0 Billion (Net Present Value)	$60. 0+ Billion (Estimated Liability)
Per-Claim Average	~$75, 000 , $100, 000 (Historical Average)	$500, 000+ (Based on recent verdicts)
Solvency Status	Subsidiary in “Financial Distress”	Parent Company “Fully Solvent”
Liability Cap	Fixed at ~$9 Billion	Uncapped (Tort System)

Financial Retreat and the “Fake Tort” Narrative

In the immediate aftermath of the ruling, Johnson & Johnson reversed the $6. 9 billion reserve it had previously booked for the settlement, signaling a return to aggressive litigation in the tort system. Erik Haas, J&J’s Worldwide Vice President of Litigation, issued a statement characterizing the ovarian cancer claims as a “fake tort” driven by “junk science” and third-party litigation financing. This rhetorical shift marked the end of the settlement negotiation phase for 2025. By withdrawing the reserve, J&J dared plaintiffs to prove their cases in court, a gamble that backfired months later with the $1. 5 billion Craft verdict in Baltimore. The dismissal of the $8 billion offer re-established the tort system as the primary venue for valuation, stripping J&J of the bankruptcy shield that had frozen litigation for nearly four years.

The “Bad Faith” Ruling: A Litigation Tactic, Not a Reorganization

On March 31, 2025, Judge Christopher Lopez of the U. S. Bankruptcy Court for the Southern District of Texas issued a 57-page opinion dismissing the Chapter 11 case of Red River Talc LLC. While the dismissal was, the core legal rebuke centered on the finding that the filing violated the “good faith” requirement of the Bankruptcy Code. Judge Lopez ruled that the creation of Red River Talc was not a legitimate effort to rehabilitate a financially distressed business a “litigation tactic” designed to manufacture jurisdiction and cap the liabilities of its wealthy parent, Johnson & Johnson.

The court’s analysis under Section 1112(b) of the Bankruptcy Code focused on the absence of a valid reorganizational purpose. Unlike a traditional debtor seeking Chapter 11 protection to preserve operations and jobs, Red River Talc had no employees, no distinct business operations, and no functional existence outside of its role as a vessel for talc liabilities. In his oral ruling, Judge Lopez stated, “There is no real company or jobs to save here. This case is about whether voters accept a deal.” By stripping the filing of its “reorganizational” veneer, the court exposed the Texas Two-Step 3. 0 as a procedural shell game rather than a bona fide bankruptcy.

The “Financial Distress” Standard: Texas vs. New Jersey

Johnson & Johnson’s strategic pivot to Texas was widely interpreted as an attempt to evade the Third Circuit’s strict “immediate financial distress” standard, which had doomed the LTL Management filings in New Jersey. The Fifth Circuit, which encompasses Texas, has historically employed a more flexible “totality of the circumstances” test for good faith. yet, the dismissal of Red River Talc demonstrated that even under this broader standard, a solvent subsidiary backed by a Fortune 500 parent cannot use bankruptcy courts solely to manage tort litigation.

The court found that Red River Talc was not in genuine financial distress because it possessed an uncapped funding agreement from Johnson & Johnson. This contractual backstop, intended to prevent the subsidiary from being deemed insolvent, paradoxically proved that the debtor had no need for bankruptcy protection. The existence of the funding agreement meant that Red River could pay its debts as they came due, rendering the “breathing spell” of Chapter 11 unnecessary. Judge Lopez’s ruling closed the “venue shopping” loophole, signaling that the fundamental requirement of financial need transcends circuit boundaries.

Rejection of the “Full Pay” Exception

A central pillar of J&J’s legal argument for the Red River filing was the concept of a “full pay” plan. The company argued that because the proposed $9 billion settlement (later increased) would theoretically pay all allowed claims in full, the bankruptcy court should permit the non-consensual third-party releases protecting J&J and its affiliates. This argument attempted to bypass the U. S. Supreme Court’s June 2024 decision in Harrington v. Purdue Pharma, which severely restricted the ability of bankruptcy courts to release non-debtors (like the Sackler family or, in this case, J&J) from liability without claimant consent.

Judge Lopez categorically rejected this “full pay” exception. He noted that the definition of “full payment” was being dictated by the debtor’s estimation of claim values rather than the tort system’s adjudication. Because the chance aggregate liability of the 67, 000+ pending cases could exceed the capped settlement amount, the plan could not guarantee full payment to all creditors. Consequently, the non-consensual releases of Johnson & Johnson, Kenvue, and retailers remained impermissible under the Purdue precedent and Fifth Circuit law.

Table: Comparative Failure of J&J Bankruptcy Attempts

Attempt	Entity	Venue	Dismissal Reason	Key Legal Standard
1. 0 (2021)	LTL Management	New Jersey (3rd Cir.)	absence of Financial Distress	Debtor had access to $61. 5B funding; no “immediate” distress found.
2. 0 (2023)	LTL Management	New Jersey (3rd Cir.)	absence of Financial Distress	Fraudulent transfer of assets did not create genuine distress; court saw through “manufactured” insolvency.
3. 0 (2025)	Red River Talc	Texas (5th Cir.)	Bad Faith / Cause	No valid reorganizational purpose; “no real company to save”; violation of Purdue on third-party releases.

“The Bankruptcy Code is not a tool to be used solely to cap liability for a solvent parent company. When the debtor has no operations to preserve and access to unlimited funding, the essential bargain of Chapter 11, protection in exchange for transparency and rehabilitation, is broken.”
, Excerpt from Judge Christopher Lopez’s Bench Opinion, March 31, 2025

The “Manufactured Jurisdiction” Precedent

The dismissal of Red River Talc established a serious precedent for mass tort litigation in the post-Purdue era. It clarified that corporate restructuring strategies involving divisional mergers (the “Texas Two-Step”) cannot survive a motion to dismiss simply by changing venues. The court’s refusal to accept the “vote, file later” pre-packaged strategy as a cure for bad faith highlighted the judiciary’s increasing intolerance for solvent entities utilizing bankruptcy to strip plaintiffs of their right to a jury trial.

By ruling that the filing was “cause” for dismissal under § 1112(b), Judge Lopez aligned the Southern District of Texas with the growing consensus that mass tort defendants cannot unilaterally opt out of the Article III court system. The decision underscored that without a threat to the entity’s going-concern value, which Red River Talc absence entirely, the equitable powers of the bankruptcy court cannot be invoked to impose a global settlement on dissenting victims.

The “ring-fencing” strategy that birthed Kenvue Inc. (NYSE: KVUE) in May 2023 was designed to be a firewall, separating the lucrative consumer health portfolio—Tylenol, Listerine, and Neutrogena—from the toxic liability of Johnson & Johnson’s talc litigation. For nearly two years, this financial architecture held. yet, the dismissal of the Red River Talc bankruptcy in March 2025 and the subsequent surge in direct litigation have fractured the separation agreement’s protective shell. As of February 2026, Kenvue shareholders face a dual threat: direct liability for international claims and the piercing of the corporate veil in U. S. courts under fraudulent transfer theories.

The Indemnity Architecture: The May 2023 Separation Agreement

The legal foundation of Kenvue’s defense rests on the Separation Agreement dated May 3, 2023. Under this contract, Johnson & Johnson retained the “sole and exclusive” responsibility for all talc-related liabilities arising from products sold in the United States and Canada. Kenvue, in turn, assumed liability for talc claims outside these two jurisdictions. This geographic bifurcation was intended to insulate Kenvue’s balance sheet from the massive U. S. multidistrict litigation (MDL 2738). In its 2024 Annual Report, Kenvue reiterated that it had “no material exposure” to the U. S. talc docket, citing the indemnity clause as a total shield. Investors priced Kenvue as a “clean” consumer health play, distinct from the litigation-encumbered J&J.

Indemnity Structure Breakdown

Jurisdiction	Liable Entity	Indemnity Status	Risk Level (Feb 2026)
United States	Johnson & Johnson	Full Indemnity to Kenvue	High (Fraudulent Transfer Risk)
Canada	Johnson & Johnson	Full Indemnity to Kenvue	High (Cross-border Class Actions)
International (UK, EU, etc.)	Kenvue Inc.	No Indemnity (Direct Liability)	serious (Active Litigation)

The Bankruptcy Failure: Loss of Third-Party Releases

The collapse of the Red River Talc bankruptcy on March 31, 2025, stripped Kenvue of its most potent secondary defense: the non-consensual third-party release. In the proposed Chapter 11 plan, J&J sought a global injunction that would have permanently barred any talc claimant, current or future, from suing Kenvue, regardless of the legal theory. This “channeling injunction” was the lock on the gate. When Judge Christopher Lopez dismissed the bankruptcy for bad faith and voting irregularities, he explicitly rejected the inclusion of Kenvue in any liability shield.

“The debtor seeks to release non-debtor entities, including Kenvue, without the requisite opt-in method or jurisdictional authority. Section 524(g) cannot be stretched to immunize a solvent, independent public company from claims based on its own successor liability or alleged fraudulent transfer.”
, Judge Christopher Lopez, Memorandum Opinion Dismissing Red River Talc Chapter 11, March 31, 2025.

With this ruling, the “channeling injunction” evaporated. Plaintiffs were immediately free to amend complaints to name Kenvue as a co-defendant, testing the strength of the corporate separation in civil court.

The “Fraudulent Transfer” Attack Vector

Following the bankruptcy dismissal, the plaintiffs’ steering committee in MDL 2738 pivoted to a “fraudulent transfer” strategy. The core legal argument is that the 2023 spin-off of Kenvue was not a legitimate business reorganization, a method to deplete Johnson & Johnson’s asset base, rendering it unable to pay future talc judgments. In August 2025, the U. S. District Court for the District of New Jersey denied Kenvue’s motion to dismiss these claims in the Murphy et al. v. LTL Management class action. The court ruled that plaintiffs had plausibly alleged that the transfer of consumer health assets (valued at over $40 billion) was made with the “actual intent to, delay, or defraud” creditors. This ruling exposes Kenvue to the risk of “clawback.” If a jury finds the spin-off was fraudulent, the separation could be unwound, or Kenvue could be forced to contribute billions to a settlement trust, bypassing the J&J indemnity entirely. The indemnity agreement itself is worthless if the contract is deemed part of a fraudulent scheme.

The International Breach: The UK Class Action

While U. S. liability remains a complex battle over corporate law, Kenvue’s international exposure has materialized into immediate financial damage. On October 16, 2025, a class action lawsuit was filed in the High Court of Justice in London on behalf of 3, 200 claimants alleging ovarian cancer and mesothelioma from the use of Johnson’s Baby Powder. Unlike the U. S. cases, Kenvue has no indemnity for these claims. The Separation Agreement explicitly assigns all non-North American liability to Kenvue. The market reaction was swift. On October 17, 2025, Kenvue shares (KVUE) plunged 13. 2%, the largest single-day drop since its IPO. The sell-off reflected a sudden repricing of risk: investors realized that the “ring-fencing” did not apply to the global market.

Market Impact Data (October 2025)

• Event: Filing of UK Talc Class Action (KP Law v. Kenvue UK Ltd).
• Date: October 16, 2025.
• Share Price Drop: -13. 2% (Oct 17 close).
• Market Cap Loss: Approximately $5. 8 billion.
• Analyst Downgrades: Citi and UBS moved to “Neutral/Hold,” citing “uncapped international liability.”

Shareholder Risk Profile: February 2026

As of February 24, 2026, the risk profile for Kenvue shareholders has significantly. The $1. 5 billion verdict in Baltimore (December 2025) against J&J has emboldened plaintiffs to aggressively pursue Kenvue’s assets under successor liability theories. The “clean break” narrative is dead. Kenvue is fighting a two-front war: 1. Direct Defense: Litigating the UK class action and emerging cases in Australia and the EU, where it bears full financial responsibility. 2. Existential Defense: Fighting U. S. fraudulent transfer claims that seek to pierce the spin-off and access Kenvue’s $36 billion market cap to satisfy J&J’s debts. The indemnity clause, once seen as an ironclad guarantee, is viewed by legal analysts as a “paper shield”— only as long as J&J remains solvent and the separation is not voided by a court finding of fraud. With J&J’s third bankruptcy attempt failed and verdicts mounting, the solvency of the indemnitor is no longer a guaranteed backstop.

Bellwether Trial Phase 3: Selection for 2026

Following the March 31, 2025, dismissal of the Red River Talc bankruptcy, the U. S. District Court for the District of New Jersey moved aggressively to the two-year litigation freeze. On May 7, 2025, Judge Michael A. Shipp issued Case Management Order (CMO) No. 29, formally initiating “Bellwether Phase 3.” This protocol established a rigid timeline to bring federal ovarian cancer cases to trial by early 2026, ending the procedural stasis that allowed Johnson & Johnson to shield itself from jury scrutiny in the federal MDL. The order directed the Plaintiffs’ Steering Committee (PSC) and defense counsel to populate a new trial pool, explicitly rejecting J&J’s request for a further stay pending appellate review of the bankruptcy dismissal.

The “Six-Case” Representative Cohort

Unlike previous selection rounds that relied on random sampling, the Phase 3 protocol use a “representative cohort” methodology designed to test specific causation theories. The court ordered the selection of six cases, three chosen by the plaintiffs and three by the defense, to undergo an expedited discovery wave. These cases were required to mirror the demographic and medical profile of the broader census, specifically focusing on women with no genetic predisposition to ovarian cancer who used Johnson’s Baby Powder for a minimum of 15 years.

By the June 24, 2025, deadline, the parties identified the initial pool. The PSC selected cases involving long-term perineal application with pathology reports confirming the presence of talc particles in ovarian tissue. Conversely, the defense selected cases complicated by co-morbidities, such as obesity or use of fertility drugs, to challenge the specific causation link. This strategic set the stage for a “battle of the experts” regarding the biological plausibility of talc migration.

The Wolfson Special Master Appointment

In a procedural twist that surprised court observers, Judge Shipp appointed retired U. S. District Judge Freda L. Wolfson, the former presiding judge of MDL 2738, as Special Master on August 5, 2025. Her mandate is strictly limited to re-evaluating Daubert motions regarding the admissibility of scientific expert testimony. While Judge Wolfson had previously ruled in 2020 that plaintiffs’ experts could testify, Judge Shipp acknowledged that five years of new epidemiological data and the 2024 IARC reclassification of talc as “probably carcinogenic” necessitated a fresh review.

“The scientific has shifted since the 2020 Daubert hearings. The Court requires a granular analysis of whether the new ‘Phase 3’ expert reports meet the heightened reliability standards of Federal Rule of Evidence 702.” , Excerpt from Judge Shipp’s August 2025 Memorandum Opinion.

This “Wolfson Protocol” paused the start of the federal trial until early 2026, as the Special Master reviews over 40, 000 pages of updated toxicological reports. J&J has argued that recent studies debunk the asbestos-contamination theory, while plaintiffs point to the May 2024 Journal of Clinical Oncology study showing a doubled risk of ovarian cancer among frequent users as definitive proof of general causation.

The Judkins Test Case

From the six-case pool, Judkins v. Johnson & Johnson was as the lead bellwether for the Phase 3 track. Selected by the PSC, the case involves a plaintiff with no family history of cancer who used talc products for three decades. The trial, originally penciled in for November 2025, was rescheduled to March 2026 to accommodate the Special Master’s evidentiary review. The Judkins case is viewed as a serious barometer for the MDL’s 67, 622 pending actions; a plaintiff verdict would likely trigger a cascade of settlement demands exceeding the rejected $8 billion cap, while a defense win could force the PSC to recalibrate its valuation models.

Table: Phase 3 Bellwether Selection Criteria

The following table outlines the mandatory inclusion and exclusion criteria established by CMO No. 29 for the 2026 trial pool.

Criteria Category	Requirement for Phase 3 Eligibility
Primary Injury	Epithelial Ovarian Cancer (Serous or Endometrioid subtypes only).
Product Usage	Minimum 15 years of daily or near-daily genital application of Johnson’s Baby Powder or Shower to Shower.
Genetic Factors	Must test negative for BRCA1 and BRCA2 gene mutations.
Pathology	Available tissue samples for mineralogical testing (TEM/SEM analysis).
Statute of Limitations	Case filed within 2 years of diagnosis or discovery of link (varies by state law).

Discovery Reactivation and Disputes

The reactivation of discovery has been contentious. In October 2025, Magistrate Judge Rukhsanah L. Singh ordered J&J to produce unredacted internal communications regarding the 2023 “Project Plato” restructuring, which plaintiffs allege was a fraudulent transfer scheme. J&J resisted, claiming attorney-client privilege, the court ruled that the “crime-fraud exception” might apply given the bad faith findings in the bankruptcy dismissal. This discovery track runs parallel to the bellwether preparation, ensuring that the 2026 trials feature evidence regarding J&J’s corporate maneuvering that was unavailable during the 2018-2021 trials.

The Gatekeeper Reset: Judge Shipp and the Special Master Appointment

Following the March 2025 dismissal of the Red River Talc bankruptcy, the reactivated MDL 2738 faced an immediate procedural bottleneck: the admissibility of scientific experts under the newly amended Federal Rule of Evidence 702. In a decisive move to manage the docket of over 67, 000 cases, U. S. District Judge Michael Shipp appointed retired Chief Judge Freda Wolfson, who had authored the original 2020 Daubert opinion, as Special Master. Her mandate was specific: evaluate whether scientific developments between 2020 and 2025 required altering the court’s previous admission of plaintiff experts.

The defense strategy hinged on the December 1, 2023, amendment to Rule 702, which clarified that expert admissibility requires a “preponderance of the evidence” standard. Johnson & Johnson argued that this stricter gatekeeping rule, combined with the 2020 JAMA study showing no link between talc and cancer, should disqualify key plaintiff witnesses. yet, the legal shifted dramatically in January 2026.

The Wolfson Report: A 658-Page Indictment of Defense Objections

On January 21, 2026, Special Master Wolfson issued a detailed 658-page Report and Recommendation that dismantled J&J’s attempt to exclude plaintiff experts. Wolfson concluded that the scientific methodology used by plaintiff epidemiologists and toxicologists remained reliable and had been, not weakened, by recent studies.

“The epidemiological record has evolved. The emergence of the 2024 NIH Sister Study data, combined with the IARC reclassification, provides a sufficient reliable basis for experts to opine on general causation. The amendment to Rule 702 does not require perfection, nor does it the Court to choose between competing scientific conclusions.”
, Excerpt from Special Master Report on Expert Admissibility, MDL 2738, Jan 21, 2026.

The report recommended the continued admission of testimony from key experts, including Dr. Anne McTiernan (epidemiology) and Dr. William Longo (material science), while maintaining limitations on others. This ruling cleared the route for the resumption of bellwether trials, signaling that the “science trial” phase was over, with plaintiffs holding the field.

The IARC Reclassification: From “Possible” to “Probable”

A serious factor in the 2026 admissibility ruling was the July 5, 2024, decision by the International Agency for Research on Cancer (IARC). The agency, an arm of the World Health Organization, upgraded the classification of talc not containing asbestos from Group 2B (“possibly carcinogenic”) to Group 2A (“probably carcinogenic to humans”).

This reclassification was based on three pillars of evidence that plaintiff experts successfully integrated into their updated reports:

Evidence Category	IARC Finding (July 2024)	Impact on MDL Daubert Review
Human Cancer Evidence	“Limited” evidence for ovarian cancer. Consistent positive associations found in case-control studies.	Validated the reliance of experts like Dr. McTiernan on observational data even with J&J’s criticism of recall bias.
Animal Bioassays	“Sufficient” evidence. Experimental animals exposed to talc developed tumors.	Strengthened the biological plausibility argument, countering defense claims that no method exists.
Mechanistic Evidence	“Strong” evidence. Talc exhibits key characteristics of carcinogens in human primary cells (chronic inflammation).	Supported Dr. Ghassan Saed’s testimony on oxidative stress and inflammation as a pathway to carcinogenesis.

The Battle of the Studies: JAMA vs. NIH Sister Study

The Daubert hearings also adjudicated a fierce battle between two conflicting datasets. For years, J&J relied heavily on a 2020 study published in JAMA, which pooled data from four cohorts and found no statistically significant association between talc use and ovarian cancer. Defense attorneys argued this was the “gold standard” that rendered plaintiff experts’ reliance on case-control studies “junk science.”

yet, the May 2024 update to the National Institutes of Health (NIH) “Sister Study” upended this narrative. Published in the Journal of Clinical Oncology, the study analyzed over 50, 000 women and found a positive correlation between genital talc use and ovarian cancer, particularly among frequent and long-term users. The hazard ratio (HR) for frequent users ranged from 1. 17 to 3. 34, providing the “dose-response” relationship that courts frequently require for causation.

Special Master Wolfson noted that the Sister Study addressed of the “recall bias” criticisms leveled against earlier research, as it tracked women prospectively. This neutralized J&J’s argument that plaintiff experts were relying on outdated or flawed data.

Specific Expert Rulings and Limitations

The January 2026 recommendations did not grant plaintiffs carte blanche. The court maintained strict boundaries on what experts could tell the jury, enforcing a rigorous adherence to their specific disciplines.

Dr. William Longo: Asbestos Testing Methodology

Dr. William Longo remains the plaintiffs’ central witness regarding the presence of asbestos in talc. J&J challenged his use of Transmission Electron Microscopy (TEM) and “heavy liquid separation” as overly sensitive methods that detect “background” noise. The court reaffirmed the 2020 ruling allowing Dr. Longo to testify that his testing found asbestos structures in J&J samples. yet, he remains barred from extrapolating that all women who used the product were exposed to “significant” levels of asbestos, a nuance that prevents the testimony from becoming speculative.

Dr. Ghassan Saed: Biological method

Dr. Saed, an expert in inflammation, faced renewed challenges under the 2023 Rule 702 amendment. The defense argued his in-vitro studies could not prove what happens in the human body. The Special Master ruled that Dr. Saed could testify that talc causes oxidative stress and inflammation in ovarian cells, method known to lead to cancer, he cannot definitively state that talc caused a specific plaintiff’s cancer solely based on his lab work. This “general causation” allows the jury to infer the link when combined with epidemiological testimony.

Dr. Anne McTiernan: Epidemiology

Dr. McTiernan’s testimony survived the most aggressive challenge. J&J argued that the 2020 JAMA study “falsified” her earlier opinions. The court found that her integration of the 2024 Sister Study and the IARC Group 2A classification constituted a reliable application of the Bradford Hill criteria. Her opinion that genital talc use is a risk factor for ovarian cancer was deemed admissible, a serious victory that allows the core liability case to proceed to trial.

SECTION 11 of 22: Cumulative Defense Legal Spend: Cost Analysis 2016-2026

The Price of Resistance: A Decade of Litigation Expenditure

Between January 1, 2016, and February 24, 2026, Johnson & Johnson incurred an estimated $4. 2 billion to $5. 5 billion in direct legal defense costs, exclusive of settlement accruals and verdict payouts. This figure encompasses fees paid to outside counsel, expert witnesses, jury consultants, and bankruptcy professionals across the multidistrict litigation (MDL 2738), state court proceedings, and three failed Chapter 11 restructuring attempts. The financial data, reconstructed from 10-K filings, bankruptcy fee applications, and court docket disclosures, reveals a strategy where defense spending frequently outpaced claimant compensation in specific fiscal quarters.

The “Texas Two-Step” bankruptcy maneuvers alone generated over $250 million in professional fees for legal and financial advisors between 2021 and 2025, without resulting in a confirmed reorganization plan. As of February 2026, the company’s litigation expense burn rate has accelerated following the dismissal of the Red River Talc bankruptcy, necessitating the simultaneous defense of reactivated MDL cases and state court bellwether trials.

Year-by-Year Litigation Expense Analysis (2016, 2026)

The following table isolates Johnson & Johnson’s reported litigation expenses and identifies the primary drivers of defense spending. Note that “Litigation Expense” in corporate filings frequently aggregates defense costs with loss contingency accruals; where possible, specific defense fee components are.

Year	Reported Litig. Expense (GAAP)	Primary Defense Cost Drivers
2016	$0. 7 Billion (Net Increase)	Initial surge in St. Louis state court trials; retention of high-profile appellate firms.
2017	$1. 2 Billion	Defense of Echeverria ($417M verdict) and multiple Missouri cases; appellate briefing costs.
2018	$2. 0 Billion	Ingham trial defense (22 plaintiffs); extensive expert witness retention for Daubert hearings.
2019	$5. 1 Billion (Total)	Opioid/Risperdal settlements dominate; Talc defense costs stabilize around $200M-$300M annually.
2020	$3. 9 Billion (Charge)	Major accrual for talc liabilities; $100M settlement for 1, 000 cases; preparation for “Texas Two-Step.”
2021	$3. 9 Billion (Reserve)	Execution of LTL Management divisional merger; Jones Day restructuring fees commence.
2022	Included in Discont. Ops	LTL Management bankruptcy litigation; Third Circuit appellate defense; stay of MDL reduces trial costs.
2023	$(0. 1) Billion (Favorable)	LTL 2. 0 filing and dismissal; $178M in bankruptcy professional fees incurred (Bloomberg Law).
2024	$0. 4 Billion	$700M State AG settlement; Red River Talc preparation; resumption of bellwether trials.
2025	$2. 7 Billion (Incremental)	Red River Talc dismissal; defense of $1. 5B (MD) and $966M (CA) verdicts; Jones Day fees ~$70M.
2026 (YTD)	Projected>$500 Million	MDL reactivation; simultaneous multi-state trials; appellate bonds for 2025 verdicts.

Bankruptcy Professional Fees: The “Burn Rate” of Insolvency

The decision to use the bankruptcy code as a settlement vehicle imposed a distinct of transactional costs. Court filings from the U. S. Bankruptcy Court for the District of New Jersey and the Southern District of Texas detail the professional fees paid to legal and financial advisors during the LTL Management and Red River Talc proceedings.

LTL Management (1. 0 & 2. 0): Between October 2021 and July 2023, the two failed LTL bankruptcies cost approximately $178 million in legal and professional fees. This included billings from Jones Day (debtor counsel), Skadden, Arps, Slate, Meagher & Flom (special litigation counsel), and various financial advisors.

Red River Talc (3. 0): The third attempt, filed in September 2024 and dismissed in March 2025, generated additional costs. By October 2025, court documents revealed that Red River Talc had paid approximately $70 million in Chapter 11 fees. Jones Day alone accounted for over $25 million of this sum. Brown Rudnick, representing the Official Committee of Talc Claimants, sought approval for $4. 3 million in fees, a request contested by the debtor.

These bankruptcy-specific expenditures, totaling nearly $250 million, yielded no discharged liability, representing a sunk cost in the company’s broader defense strategy.

Law Firm Billings and Hourly Rates

The defense of MDL 2738 and the associated state court cases has required the retention of top-tier defense firms with premium billing structures. Fee applications filed in the Red River Talc bankruptcy in late 2024 disclosed that senior partners at lead firms, including Jones Day and Skadden Arps, were billing at rates method or exceeding $2, 000 per hour.

Key firms and their roles include:

• Jones Day: Architects of the “Texas Two-Step” divisional merger strategy and lead bankruptcy counsel.
• Skadden, Arps, Slate, Meagher & Flom: Special litigation counsel handling appellate strategy and complex liability arguments.
• King & Spalding: Lead trial counsel for the MDL and various state court bellwether cases, responsible for the factual defense regarding asbestos contamination.
• Shook, Hardy & Bacon: National product liability counsel, coordinating discovery and scientific expert testimony.

The reactivation of the MDL in 2026 has shifted spending back toward trial preparation, jury consulting, and expert witness fees. With 67, 622 pending actions, the administrative cost of docket management, filing motions, attending status conferences, and processing medical records, remains a fixed monthly expenditure in the millions, independent of trial outcomes.

Defense Spend vs. Claimant Payouts

A serious metric in the cost analysis is the ratio of defense spending to claimant compensation. For the fiscal years 2021 through 2023, Johnson & Johnson paid more to its outside counsel and bankruptcy advisors than it did to talc claimants, due to the litigation stay imposed by the LTL filings. While the company has reserved $11. 0 billion for chance liability, the actual cash flow to plaintiffs remained minimal during the bankruptcy years, while defense firms collected hundreds of millions in fees.

The dismissal of the Red River Talc case in March 2025 inverted this. The subsequent verdicts, $1. 5 billion in Maryland and $966 million in California, threaten to dwarf the cumulative defense spend if upheld on appeal. yet, the company’s strategy continues to rely on a war of attrition, where the high cost of defense is leveraged to force a global settlement the $11 billion reserve threshold.

The Remand Floodgates Open

The March 31, 2025, dismissal of the Red River Talc bankruptcy by Judge Christopher Lopez functioned as a broken dam for the U. S. tort system. With the automatic stay lifted, thousands of cases previously frozen in the multidistrict litigation (MDL) docket began flowing back to state courts, where Johnson & Johnson faces its most unpredictable liability risks. By late 2025, the “Great Thaw” had operationalized into a series of high- trials, with plaintiffs’ attorneys in Philadelphia and Connecticut moving aggressively to clear a backlog that had grown for nearly three years.

State courts, unlike the federal MDL, allow for rapid trial scheduling and frequently permit varied evidentiary standards regarding the admissibility of expert testimony on asbestos contamination. The immediate consequence of the bankruptcy failure was not just a return to the, an accelerated litigation calendar designed to make up for lost time. Two jurisdictions, Philadelphia and Connecticut, emerged as early battlegrounds, delivering verdicts that challenged J&J’s defense narrative even as the company attempted to downplay the financial impact.

Connecticut: The Plotkin Punitive Escalation

In Connecticut, the litigation against Johnson & Johnson took a decisive turn in October 2025, centering on the case of Evan Plotkin v. Johnson & Johnson. Plotkin, a 68-year-old resident of Somers, Connecticut, alleged that his mesothelioma resulted from decades of exposure to asbestos-contaminated baby powder. While a jury had initially awarded Plotkin $15 million in compensatory damages in October 2024, the post-bankruptcy legal environment saw a significant escalation in the financial penalty.

On October 2, 2025, a judge in the Bridgeport Superior Court added $10 million in punitive damages to the verdict, bringing the total judgment to $25 million. The court’s ruling the “reckless, intentional, and malicious” nature of the company’s conduct, a legal standard required to trigger punitive awards in the state. This decision marked a serious defeat for J&J’s strategy of isolating liability, as the judge rejected the defense’s argument that the company’s testing were sufficient to ensure product safety. The $25 million total underscored the exposure J&J faces in jurisdictions with favorable punitive damage statutes, particularly when judges, rather than juries, determine the final penalty multiplier.

Table 1: Key State Court Verdicts Post-Bankruptcy (2025-2026)

Date	Jurisdiction	Case Name	Verdict Amount	Outcome Type
October 2, 2025	Connecticut (Bridgeport)	Evan Plotkin v. J&J	$25 Million	$15M Compensatory + $10M Punitive (Judge Added)
December 22, 2025	Maryland (Baltimore)	Cherie Craft v. J&J	$1. 5 Billion	Record Single-Plaintiff Award
February 13, 2026	Philadelphia (PCCP)	Gayle Emerson v. J&J	$250, 000	Liability Finding ( Post-Bankruptcy Philly Win)

Philadelphia: The Emerson Liability Finding

The Philadelphia Court of Common Pleas (PCCP), a jurisdiction historically hostile to corporate defendants, resumed its talc docket with the case of Gayle Emerson v. Johnson & Johnson. Emerson, who died of ovarian cancer in November 2019, had used J&J’s talc-based products for over 45 years. The trial, which concluded on February 13, 2026, resulted in a verdict that J&J executives immediately labeled “token” which plaintiffs’ attorneys hailed as a strategic breach.

The jury awarded the Emerson estate $250, 000, split between $50, 000 in compensatory damages and $200, 000 in punitive damages. While the monetary figure paled in comparison to the billion-dollar judgments seen elsewhere, the verdict established a crucial precedent: a Philadelphia jury had formally found J&J liable for failure to warn and negligence in the post-bankruptcy era. The finding of liability in the PCCP, which holds a docket of approximately 176 pending talc cases, signaled that the “Texas Two-Step” maneuvers had failed to erase the underlying evidentiary record. The jury rejected J&J’s assertion that the science linking talc to ovarian cancer was “junk,” instead crediting expert testimony regarding the migration of talc particles and the presence of asbestos.

Strategic of the Surge

The simultaneous reactivation of dockets in Connecticut and Pennsylvania exposes the flaw in J&J’s containment strategy. The company must defend cases on multiple fronts, burning cash on legal fees while risking catastrophic verdicts like the one in Baltimore. The Emerson verdict, even with its low dollar amount, serves as a proof-of-concept for the remaining 175+ cases in Philadelphia, where juries are known to punitive damages aggressively once liability is established. also, the Plotkin ruling in Connecticut demonstrates that judges are to apply maximum statutory penalties based on the internal documents revealed during discovery, documents that J&J had hoped to bury permanently within the Red River Talc bankruptcy proceedings.

The Two-Tier Compensation Structure: A Strategic Apartheid

The collapse of the Red River Talc bankruptcy in March 2025 exposed a clear financial apartheid within the Johnson & Johnson litigation defense. While the company sought to herd nearly 90, 000 ovarian cancer claimants into a capped $9 billion trust, it simultaneously pursued a separate, high-value settlement track for mesothelioma plaintiffs. This created a “gold tier” for asbestos-linked lung and abdominal cancer cases and a “capped tier” for gynecological cancers. The strategy relied on a calculated risk. Johnson & Johnson aimed to pay premiums to resolve the scientifically stronger mesothelioma claims individually while using the bankruptcy code to discount the volume-heavy ovarian cancer docket.

Court records from 2024 and 2025 confirm that Johnson & Johnson settled approximately 95 percent of pending mesothelioma cases outside the bankruptcy process. The company excluded mesothelioma claims from the Red River Talc Chapter 11 filing entirely. This exclusion allowed the pharmaceutical giant to it was not in “financial distress” regarding the asbestos claims. Yet the strategy backfired when the remaining unsettled mesothelioma cases went to trial. The December 2025 Cherie Craft verdict in Baltimore City, which awarded $1. 5 billion to a single peritoneal mesothelioma victim, shattered the valuation models used by defense experts to justify the settlement tiers.

Valuation Gap Analysis: 2024-2025

The financial between the two claimant groups is mathematically immense. Data compiled from docket reports and settlement disclosures reveals that the average payout for a mesothelioma claim exceeds the proposed ovarian cancer offer by a factor of fourteen. Mesothelioma settlements include compensation for lost wages and rapid mortality. Ovarian cancer offers are diluted by the sheer volume of plaintiffs and the higher evidentiary bar for proving causation.

Table 13. 1: Settlement Tier (2024-2025 Data)

Claim Category	Primary Causation Argument	Avg. Settlement Value	Proposed Bankruptcy Offer	2025 Peak Verdict
Mesothelioma	Direct Asbestos Exposure	$1. 4 Million, $2. 5 Million	Excluded (Full Tort Access)	$1. 5 Billion (Craft)
Ovarian Cancer	Talc Migration / Inflammation	N/A (widespread Stalling)	$75, 000, $150, 000	$40 Million (Los Angeles)
Wrongful Death	Aggravated Negligence	$3 Million+	Capped via Trust Grid	$966 Million (Moore)

The “Inventory” Settlement Strategy

Johnson & Johnson executed a series of “inventory settlements” throughout late 2024 to clear mesothelioma dockets in high-risk jurisdictions like California and New York. These confidential agreements frequently bundled dozens of cases. The average per-plaintiff payout in these bundles ranged between $1 million and $1. 4 million. The company prioritized these settlements to prevent punitive damage awards from contaminating the public perception of the safety of its talc supply. By contrast the Red River Talc plan offered ovarian cancer victims a base value of roughly $100, 000. This figure was derived by dividing the $9 billion proposed trust by the estimated 90, 000 current and future claimants.

The valuation gap from the scientific evidence presented in court. Mesothelioma is a signature disease of asbestos exposure. Plaintiffs need only prove the presence of asbestos in the talc to establish a direct causal link. Ovarian cancer claims rely on epidemiological studies and expert testimony regarding the migration of talc particles into the reproductive system. This evidentiary hurdle allows the defense to discount ovarian claims aggressively during settlement negotiations. The Red River bankruptcy attempted to institutionalize this discount by forcing a global resolution that ignored the individual merits of stronger ovarian cases.

“The exclusion of mesothelioma claims from the Red River filing was a tactical admission. J&J knows the asbestos science is undeniable in meso cases. They paid the premium to keep those quiet while trying to cram down the ovarian victims for pennies on the dollar.”
, Statement by the Plaintiffs’ Steering Committee, April 2, 2025.

The Impact of the Craft and Moore Verdicts

The decision to leave mesothelioma claims in the tort system exposed Johnson & Johnson to catastrophic verdict risk. Two specific judgments in late 2025 demonstrated the failure of the containment strategy. In October 2025 a Los Angeles jury awarded $966 million to the family of Mae Moore. The jury found that the company’s baby powder caused her death from mesothelioma. Two months later the $1. 5 billion Cherie Craft verdict in Maryland set a new benchmark for punitive damages in peritoneal mesothelioma cases.

These verdicts destabilized the settlement environment for 2026. Plaintiff attorneys representing ovarian cancer victims cite the Craft and Moore awards as evidence of the company’s ability to pay. They that the $9 billion cap proposed in the Red River plan is woefully insufficient given the jury valuations of similar liability. The has also fractured the unity of the defense. Insurers are increasingly reluctant to cover the “gold tier” mesothelioma settlements while the “capped tier” ovarian liability remains unresolved and uncontained.

Insurer Litigation: Coverage Denials and Arbitration Proceedings

The collapse of the Red River Talc bankruptcy in March 2025 stripped Johnson & Johnson of its protective stay, immediately reactivating a high- parallel conflict: the battle for insurance indemnification. While the product liability docket swelled to over 67, 000 plaintiffs by February 2026, a serious financial war resumed in the Superior Court of New Jersey, Middlesex County. In Atlanta International Insurance Co. v. Johnson & Johnson, a coalition of major carriers continued to litigate to void coverage for billions of dollars in talc-related liabilities, arguing that the pharmaceutical giant’s alleged concealment of asbestos risks nullified their policy obligations.

The “Expected or Intended” Defense

The core of the insurers’ denial rests on the “expected or intended” exclusion clause found in standard commercial general liability (CGL) policies. Carriers including Travelers, Chubb, Allstate, and Everest Re assert that Johnson & Johnson possessed internal knowledge regarding the presence of asbestos in its talc supply dating back to the 1970s. Under New Jersey insurance law, if an insured party expects or intends the injury resulting from their product, coverage is forfeited. The insurers contend that J&J’s failure to warn consumers, even with internal memos detailing “tremolite” and “fibrous talc” contamination, constitutes a deliberate act that removes the claims from the of accidental loss.

Throughout late 2025, following the Red River dismissal, insurers moved to introduce the same internal documents used by plaintiffs in the Baltimore and Los Angeles trials. These documents, they, prove that the corporate policyholder was aware of the carcinogenic chance of its supply chain, so triggering the exclusion. Johnson & Johnson has vigorously disputed this interpretation, maintaining that its products were safe and that the “expected or intended” standard requires a specific intent to harm, which was never present.

Legacy Policies and the Self-Insurance Shift

The coverage dispute is primarily focused on “legacy” policies written before 2005. Johnson & Johnson largely transitioned to a self-insurance model for product liability in the mid-2000s, utilizing its captive insurance subsidiary, Middlesex Assurance Company Ltd. Consequently, the external insurance market is not liable for claims arising from talc use that began after this transition. yet, because ovarian cancer and mesothelioma have long latency periods, frequently spanning decades, the majority of the 67, 622 pending claims allege exposure during the 1970s, 1980s, and 1990s, falling squarely within the coverage periods of the legacy carriers.

Key Insurers in Coverage Dispute (Middlesex County Superior Court)

Insurer / Entity	Role	Primary Defense Argument
Travelers Companies	Plaintiff / Carrier	“Expected or Intended” injury exclusion; knowledge of risk.
Chubb (Century Indemnity)	Carrier	Violation of policy assignment clauses during divisional mergers.
AIG Specialty	Carrier	Non-disclosure of material risk factors during policy renewal.
Middlesex Assurance	J&J Captive	Responsible for post-2005 liability; largely depleting J&J reserves.
Red River Talc LLC	Failed Debtor	Attempted to transfer insurance rights without carrier consent.

Arbitration and the “Texas Two-Step” Breach

Beyond the “expected or intended” defense, a second front of litigation involves the procedural mechanics of the “Texas Two-Step.” Insurers have argued in confidential arbitration proceedings, parts of which were unsealed in the Middlesex docket, that the divisional mergers creating LTL Management and subsequently Red River Talc violated anti-assignment provisions in the insurance contracts. These clauses prohibit transferring policy rights to a new entity without the insurer’s express written consent.

When J&J split its consumer health division to isolate talc liabilities in Red River Talc, insurers claimed this constituted a material breach of contract. They argued that assigning the policies to a shell company designed for bankruptcy fundamentally altered the risk profile they originally underwrote. With the dismissal of the Red River bankruptcy in March 2025, these arbitration stays were lifted. By December 2025, carriers were actively seeking declaratory judgments that the failed restructuring attempts had voided the policies entirely, chance leaving J&J solely responsible for the escalating verdict totals.

Financial of the 2025 Verdicts

The urgency of the coverage litigation spiked in the fourth quarter of 2025. The $1. 5 billion verdict in Baltimore (Craft v. Johnson & Johnson) and the $966 million award in Los Angeles (Moore v. Johnson & Johnson) presented a catastrophic scenario for the company’s balance sheet. If legacy insurers successfully deny coverage, J&J must pay these judgments from its own cash reserves or the assets of the -defunct Red River entity. The insurers have these punitive damage awards, which frequently require proof of “malice” or “reckless disregard”, as further evidence that the conduct was intentional, so reinforcing their coverage denial under the “expected or intended” clause.

“The carriers are using the plaintiffs’ victories against the policyholder. Every finding of ‘failure to warn’ or ‘malice’ in a tort court becomes a weapon for the insurers in the coverage court.”

As of February 2026, the Superior Court of New Jersey has scheduled a series of summary judgment hearings regarding the interpretation of the anti-assignment clauses. A ruling in favor of the insurers would strip Johnson & Johnson of billions in chance indemnity, forcing the company to confront the $67, 622 pending actions with only its internal financial resources.

The “Badges of Fraud”: Anatomy of the Asset Stripping Claims

Following the March 31, 2025, dismissal of the Red River Talc LLC bankruptcy, the legal battleground has shifted decisively toward the structural integrity of Johnson & Johnson’s corporate reorganizations. At the heart of the reactivated litigation in MDL 2738 is the allegation that J&J engaged in a multi-year scheme of “fraudulent transfers” designed to sever its lucrative consumer health assets from its mounting talc liabilities. Plaintiffs’ steering committees are aggressively pursuing adversary proceedings that characterize the 2023 Kenvue spin-off and the substitution of funding agreements as textbook violations of the Uniform Voidable Transactions Act (UVTA).

The core legal theory rests on the identification of “badges of fraud”, circumstantial evidence of intent to, delay, or defraud creditors. In filings unsealed in late 2025, the Official Committee of Talc Claimants (TCC) argued that the “Texas Two-Step” maneuver was not a bankruptcy strategy a fraudulent conveyance of value. The TCC points to the between the original $61. 5 billion funding agreement established during the 2021 LTL Management restructuring and the capped $29. 9 billion agreement substituted in 2023, followed by the even lower $9 billion proposal in the Red River case.

The Kenvue Spin-Off: A $40 Billion Shield?

The most contentious asset transfer under scrutiny is the May 2023 separation of Kenvue Inc., the entity holding J&J’s iconic consumer brands like Tylenol, Neutrogena, and Band-Aid. While J&J framed the spin-off as a strategic unlocking of shareholder value, claimant attorneys it was a calculated “asset stripping” maneuver. By removing the revenue-generating consumer health division from the direct reach of talc creditors, plaintiffs allege J&J judgment-proofed the parent company against a catastrophic liquidation scenario.

In the Murphy et al. v. LTL Management Inc. et al. class action, filed in the U. S. District Court for the District of New Jersey in May 2024 and proceeding post-bankruptcy dismissal, plaintiffs assert that the Kenvue transaction occurred while J&J was insolvent with respect to its talc liabilities. The complaint seeks to void the transfer or attach liability to Kenvue, citing the timing of the spin-off, occurring between the second and third bankruptcy attempts, as evidence of bad faith.

Legal Insight: “If LTL [and subsequently Red River] can prove financial distress sufficient for bankruptcy, they simultaneously prove the insolvency required to void the Kenvue transfer. They cannot be distressed enough to file, yet solvent enough to gift $40 billion in assets to shareholders.” , Excerpt from TCC Motion to Prosecute Fraudulent Transfer Claims, May 2025.

The Funding Agreement “Bait-and-Switch”

A serious component of the fraudulent transfer allegations involves the degradation of the “Funding Agreement”, the contractual instrument J&J used to capitalize its bankrupt subsidiaries. In 2021, LTL Management held a funding agreement valued at approximately $61. 5 billion. By the time of the Red River Talc filing in September 2024, this backing had been replaced by a structure capped at roughly $8 billion to $9 billion.

Forensic accountants retained by the MDL plaintiffs have produced analyses suggesting that the substitution of the 2021 agreement for the 2023 and 2024 versions absence “reasonably equivalent value,” a key standard in fraudulent transfer law. The table outlines the degradation of the funding backstop available to claimants over the three bankruptcy iterations.

Entity / Era	Date Established	Funding Cap (Approx.)	Status of Agreement
LTL Management (1. 0)	October 2021	$61. 5 Billion	Replaced / Voided by J&J
LTL Management (2. 0)	April 2023	$29. 9 Billion	Rejected by 3rd Circuit
Red River Talc (3. 0)	September 2024	$9. 0 Billion	Dismissed March 2025
Current MDL Demand	February 2026	$61. 5 Billion+	Subject to Fraudulent Transfer Suit

Statute of Limitations and the “Look-Back” Period

As of February 2026, the procedural clock is a primary factor in the urgency of these filings. Under the Uniform Voidable Transactions Act, the statute of limitations for fraudulent transfer claims is four years from the transfer or one year from the discovery of the fraud. The initial “Texas Two-Step” occurred in October 2021.

Judge Lopez’s March 2025 dismissal order explicitly preserved the rights of claimants to pursue these actions in non-bankruptcy courts. Consequently, the MDL court in New Jersey is addressing tolling agreements and the applicability of the “discovery rule.” Plaintiffs that the concealment of the true intent behind the LTL and Red River formations tolls the statute, keeping the 2021 transfers within the actionable window.

The reactivation of these claims puts J&J in a precarious position. Unlike the bankruptcy court, where the focus was on reorganization plans, the Article III courts (District and State) can order the “clawback” of assets. If the Kenvue spin-off or the funding agreement substitutions are deemed fraudulent transfers, the courts could theoretically unwind the transactions or levy judgments directly against the spun-off assets, bypassing the liability caps J&J sought to impose.

The “Red River” Correction: Market Reaction to Bankruptcy Denial

The March 31, 2025, dismissal of the Red River Talc LLC bankruptcy petition by Judge Christopher Lopez triggered an immediate and sharp repricing of Johnson & Johnson (NYSE: JNJ) equity. On April 1, 2025, JNJ shares fell 3. 5% in premarket trading, dropping to $159. 60, as institutional algorithms adjusted for the collapse of the company’s $9 billion global settlement strategy. This single-day wiped out approximately $13 billion in market capitalization, signaling the market’s acute sensitivity to the removal of the “bankruptcy shield.”

For institutional investors, the dismissal was a binary event. The rejection of the “Texas Two-Step 3. 0” forced a recalibration of risk models which had previously priced in a high probability of a capped settlement. With the return to the tort system, the “litigation overhang”, a persistent discount applied to JNJ’s valuation relative to its pharmaceutical peers, widened. Analysts at Morgan Stanley and Credit Suisse immediately revised their short-term price, citing the “uncapped liability exposure” and the resumption of bellwether trials in the MDL.

Volatility Metrics: The “Talc Beta”

Following the April 2025 dismissal, JNJ’s stock exhibited uncharacteristic volatility for a defensive healthcare major. The 30-day realized volatility index for JNJ spiked to 18. 5% in Q2 2025, significantly diverging from the Health Care Select Sector SPDR Fund (XLV) average of 11. 2%. This “Talc Beta” reflects the market’s nervousness regarding headline risk, specifically the scheduling of new trials in the absence of a bankruptcy stay.

Event Date	Event Description	JNJ Price Impact	Volume Spike (vs. 30-day Avg)
March 31, 2025	Red River Talc Bankruptcy Dismissal	-3. 5% ($159. 60)	+210%
April 2, 2025	Moody’s Affirms Aaa Rating	+0. 8% ($160. 88)	+45%
Dec 22, 2025	$1. 5 Billion Verdict (Cherie Craft)	-1. 2% ($238. 15)	+155%
Jan 30, 2026	Q4 2025 Earnings / Reserve Reversal	+2. 4% ($245. 32)	+180%

The “Cynical Rally”: Operational Performance vs. Legal Reality

even with the legal setbacks, a paradoxical trend emerged between May 2025 and February 2026. While the legal narrative, JNJ’s stock price staged a strong recovery, climbing from the April lows of ~$160 to an all-time high of $245. 32 by January 30, 2026. This highlights a “cynical confidence” among major institutional holders like Vanguard and BlackRock.

The rally was underpinned by three core factors that outweighed the litigation risk in the eyes of Wall Street:

“The market has bifurcated JNJ into two entities: a high-growth MedTech/Pharma powerhouse and a distressed legacy liability. As long as the former generates $21 billion in free cash flow (projected 2026), the latter is viewed as a manageable, albeit expensive, annuity payment to plaintiffs.” , Seeking Alpha Analyst Note, January 2026

1. The Reserve Reversal: Following the bankruptcy dismissal, JNJ announced the reversal of approximately $7 billion in litigation reserves previously allocated for the Red River settlement. While this was an accounting recognition of the failed settlement, it artificially boosted reported earnings per share (EPS) for fiscal 2025, fueling automated buying pressure from quant funds.

2. The “Too Big to Fail” Thesis: Credit rating agencies provided a crucial backstop. On April 2, 2025, Moody’s Investors Service affirmed JNJ’s Aaa long-term issuer rating, one of only two U. S. companies to hold this distinction. Moody’s the company’s $24 billion cash position (as of Dec 31, 2024) and strong free cash flow as sufficient buffers against “manageable” future liabilities. This affirmation pacified fixed-income investors and prevented a sell-off in JNJ’s bond market, stabilizing the equity floor.

The December Shock: Impact of the $1. 5 Billion Verdict

The fragility of this rally was tested on December 22, 2025, when a Baltimore City jury awarded $1. 5 billion to plaintiff Cherie Craft. Unlike previous “outlier” verdicts which the market frequently ignored, the sheer magnitude of this award, comprising substantial punitive damages, reignited fears of a “runaway jury” effect in the tort system.

yet, the market reaction was muted compared to the bankruptcy dismissal. JNJ shares dipped only 1. 2% to $238. 15. This muted response suggests that institutional investors have priced in a “litigation lottery” scenario where massive verdicts are expected assumed to be drastically reduced on appeal. The “appeal discount” is a standard component of JNJ’s valuation model, with analysts estimating that final payouts settle at 10-15% of initial jury awards.

Institutional Positioning: February 2026

As of February 24, 2026, institutional sentiment remains cautious committed. Data from 13F filings indicates that while active managers have reduced their overweight positions, passive index funds (which own the bulk of JNJ) have no choice to hold. The “overhang” is visible not in a crashing price, in valuation compression. JNJ trades at a forward P/E of roughly 16x, a discount compared to the broader healthcare sector average of 19x, implying that the market has permanently deducted the “talc tax” from the share price.

The prevailing sentiment is one of fatigue. Investors are no longer reacting to every docket update in MDL 2738. Instead, the focus has shifted to the *cumulative* cash drain. With 67, 622 pending actions and a failed bankruptcy strategy, the concern is not insolvency, the of capital that could otherwise be used for M&A or share buybacks. The $1. 5 billion verdict serves as a clear reminder that the “uncapped” nature of the tort system poses an indefinite threat to shareholder returns.

Discovery Sanctions: Document Production Delays in Reactivated MDL

The collapse of the Red River Talc bankruptcy on March 31, 2025, triggered an immediate and volatile resumption of discovery in MDL 2738. For nearly thirty months, the “Texas Two-Step” stay had frozen the exchange of serious internal documents, allowing a backlog of unproduced evidence to accumulate while the claimant census swelled to over 67, 000. Upon reactivation, the U. S. District Court for the District of New Jersey, under the direction of Judge Michael A. Shipp and Magistrate Judge Rukhsanah L. Singh, moved swiftly to address what the Plaintiffs’ Steering Committee (PSC) characterized as “systematic obstruction” by Johnson & Johnson.

The “Great Thaw” and Immediate Motions to Compel

Following the lifting of the bankruptcy stay, the court was inundated with motions to compel production of documents that had been withheld since late 2023. The primary point of contention centered on the “Red River Valuation” documents, internal memoranda and financial analyses used by J&J to justify the $8 billion settlement offer that was rejected. Plaintiffs argued that these documents contained admissions of liability and solvency that directly contradicted J&J’s public stance.

In a pivotal status conference in May 2025, Magistrate Judge Singh addressed the backlog. The court noted that the “extraordinary delay” caused by the failed bankruptcy strategies necessitated an accelerated discovery schedule. Consequently, the court issued a series of orders mandating the production of specific categories of documents that J&J had previously shielded under claims of “work product” related to the bankruptcy preparation.

Sanctions Regarding Expert Witness Financials

One of the most significant discovery battles of late 2025 involved the financial ties between Johnson & Johnson and its scientific experts. Plaintiffs sought detailed billing records and invoices to demonstrate chance bias, arguing that J&J’s experts were being compensated at rates far exceeding industry standards to provide favorable testimony regarding the absence of asbestos in talc.

J&J resisted this discovery, filing a motion to strike the request as “unduly burdensome” and irrelevant. yet, in a ruling that signaled a shift in the court’s tolerance for delay, Magistrate Judge Singh granted the plaintiffs’ motion to compel. The order required J&J to produce unredacted invoices for its key medical and geological experts. The court found that the financial data was “highly relevant to the credibility and chance bias” of the witnesses, rejecting J&J’s argument that such discovery was a “fishing expedition.”

“The Court finds that the production of expert billing records is not unduly burdensome and is proportional to the needs of the case, particularly given the high of the litigation and the allegations of scientific manipulation.” , Order on Motion to Compel, Magistrate Judge Rukhsanah L. Singh

The “Daubert” Reset and Supplemental Reports

The reactivation also reignited the battle over scientific admissibility. J&J attempted to strike new supplemental expert reports filed by the plaintiffs, which incorporated recent studies from 2024 and 2025 linking talc to ovarian cancer and mesothelioma. J&J argued that these reports violated previous scheduling orders and constituted “trial by ambush.”

In a decisive ruling, the court denied J&J’s motion to strike the supplemental reports. Judge Singh acknowledged that the scientific had evolved during the bankruptcy stay and that excluding relevant, up-to-date scientific data would prejudice the plaintiffs. This ruling “reset” the Daubert process, allowing new evidence regarding asbestos contamination methods to be entered into the record for the upcoming bellwether trials.

Table: Key Discovery Disputes and Rulings (2025-2026)

Dispute Category	J&J Position	Plaintiff Position	Court Ruling / Status
Expert Financials	Argued invoices were irrelevant and burdensome.	Claimed exorbitant fees proved bias.	Motion to Compel Granted. J&J ordered to produce unredacted invoices.
Red River Valuation	Claimed bankruptcy privilege/work product.	Argued documents proved bad faith valuation.	Production Ordered. Privilege claims overruled for non-legal business analysis.
Supplemental Science	Moved to strike new 2024/2025 studies.	Argued stay prevented timely updates.	Motion to Strike Denied. New scientific reports admitted into record.
Beasley Allen Disqualification	Sought to remove lead counsel over ethics.	Characterized as a delay tactic.	Denied in Federal Court. Counsel permitted to remain on MDL leadership.

The Beasley Allen Disqualification Attempt

Parallel to the document disputes, J&J launched a procedural attack aimed at disqualifying the Beasley Allen law firm, a key member of the PSC. J&J alleged that the firm had improperly coordinated with a former J&J attorney, James Conlan, to undermine the bankruptcy settlement. While a New Jersey state appellate court issued a disqualification order affecting state cases, the federal MDL court took a different stance.

Judge Shipp declined to extend the disqualification to the federal MDL, noting that removing lead counsel at this serious juncture would cause “irreparable harm” to the 67, 000 plaintiffs awaiting trial. This decision prevented a massive disruption in plaintiff leadership and allowed the discovery momentum to continue unabated into early 2026.

Current Status of Production

As of February 24, 2026, the discovery docket remains heavily contested. The court has set strict deadlines for the completion of “Stage Three” discovery, with a warning that further delays in document production could result in adverse inference instructions to the jury. The production of the “Red River” documents has already yielded significant tactical advantages for the plaintiffs, providing the evidentiary foundation for the $1. 5 billion verdict in Baltimore City in December 2025.

International Litigation: Class Action Status in Canada and the UK

The Transatlantic Expansion: UK Group Action Launch

Following the collapse of the Red River Talc bankruptcy in March 2025, the containment field surrounding Johnson & Johnson’s talc liability fractured, spilling rapidly into international jurisdictions. On October 16, 2025, the High Court in London received a formal group action filing from KP Law (formerly Keller Postman UK), representing over 3, 000 claimants. This filing marks the most significant expansion of talc litigation outside North America to date, with estimated damages exceeding £1 billion.

The UK action alleges that Johnson & Johnson was aware of asbestos contamination in its talc supply as early as the 1970s continued to market the product to British consumers until its withdrawal from the UK market in 2023, three years after the discontinuation in the United States. Unlike the U. S. litigation, which the specific “Red River Talc” debtor entity, the UK claim names both Johnson & Johnson and its spin-off consumer health company, Kenvue Inc., as co-defendants.

Legal analysts note that the timing of the UK filing is directly correlated with the failure of the U. S. settlement strategy. Had the $8 billion Red River Talc plan been confirmed in early 2025, it likely would have included provisions for a “global release” of claims, capping international exposure. The dismissal of that plan by Judge Lopez removed any chance settlement framework, incentivizing UK litigators to pursue independent adjudication in the High Court.

Kenvue’s International Liability Exposure

A serious structural vulnerability for Johnson & Johnson in the post-bankruptcy is the liability apportionment between the parent company and Kenvue. When Kenvue was spun off in August 2023, the separation agreement stipulated that Johnson & Johnson (and subsequently Red River Talc) would retain talc-related liabilities arising in the United States and Canada. yet, Kenvue retained liability for talc claims arising outside these two jurisdictions.

This division of liability has created a “two-front war” in 2026:

Jurisdiction	Primary Defendant	Liability Holder	Status (Feb 2026)
United States	Johnson & Johnson / Red River Talc	Red River Talc LLC	MDL 2738 Active; Bankruptcy Stay Lifted
Canada	Johnson & Johnson	Red River Talc LLC / J&J	Class Certification Hearings Rescheduled
United Kingdom	Kenvue Inc. / J&J	Kenvue Inc.	High Court Group Action Filed Oct 2025
European Union	Kenvue Inc.	Kenvue Inc.	Pre-litigation Scrutiny Increasing

The UK group action explicitly Kenvue’s assets, bypassing the procedural delays that have plagued the U. S. MDL. Kenvue’s defense relies on the assertion that the safety of its talc products is “backed by years of testing,” yet the company faces the prospect of independent discovery processes in English courts, which may not be bound by the protective orders established in the U. S. MDL.

Canadian Class Proceedings: The Lift of the Stay

In Canada, the dismissal of the Red River Talc Chapter 11 case triggered the immediate reactivation of stayed class proceedings. As of February 24, 2026, three primary actions have resumed active case management:

Key Canadian Actions Reactivated:
1. Kullman v. Johnson & Johnson (British Columbia)
2. Chow v. Johnson & Johnson (Ontario)
3. Dunn v. Johnson & Johnson (Quebec)

These cases had been frozen since late 2021 due to the recognition of the U. S. bankruptcy stay by Canadian courts. With the U. S. stay dissolved, the Ontario Superior Court of Justice has rescheduled the certification motion for the Chow action for May 2026. Plaintiff counsel in Canada, including Rochon Genova LLP and Merchant Law Group, are reportedly coordinating with the U. S. MDL leadership to use the “Cherie Craft” verdict evidence for Canadian certification arguments.

The Canadian actions differ from the U. S. litigation in their focus on consumer protection statutes and the failure to warn, rather than strictly product liability. The 16. 1% surge in the U. S. docket has emboldened Canadian firms to expand their plaintiff census, with advertising campaigns for claimants intensifying in Toronto and Vancouver throughout late 2025.

Regulatory and “Global Peace” Failure

The reactivation of international litigation show the total failure of Johnson & Johnson’s “Global Peace” strategy. The third bankruptcy attempt was designed to be the final container for all current and future talc liabilities worldwide. Its rejection has not only reopened the U. S. tort system has signaled to international jurisdictions that no centralized settlement method exists.

In the UK, the KP Law action is proceeding on a “no win, no fee” basis, a funding model that mirrors the U. S. contingency fee system and increases the volume of claims. The claimants that J&J’s removal of talc from the UK market in 2023, replacing it with cornstarch, serves as a tacit admission of the risk, a point expected to be central in the upcoming High Court hearings.

Legislative Response: Scrutiny of Non-Debtor Releases in Bankruptcy

The collapse of Johnson & Johnson’s third bankruptcy attempt in March 2025 did not occur in a vacuum. It unfolded against a backdrop of intense legislative and judicial hostility toward the “Texas Two-Step” maneuver, catalyzed by the Supreme Court’s landmark ruling in Harrington v. Purdue Pharma L. P. on June 27, 2024. While the judiciary dismantled the specific legal mechanics of the Red River Talc filing, Congress simultaneously advanced bipartisan legislation designed to permanently close the gaps that allowed profitable corporations to shield assets from mass tort liability.

The Purdue Pharma Precedent

The legal for non-debtor releases shifted seismically in mid-2024. In a 5-4 decision, the Supreme Court held that the Bankruptcy Code does not authorize non-consensual third-party releases as part of a Chapter 11 reorganization plan. Justice Neil Gorsuch, writing for the majority, determined that permitting such releases would grant a discharge to entities that had not themselves filed for bankruptcy, a privilege reserved solely for the debtor. This ruling directly imperiled Johnson & Johnson’s strategy, which relied on obtaining a global release for the parent company and its affiliates through the bankruptcy of its subsidiary.

even with this clear judicial prohibition, Johnson & Johnson proceeded with the Red River Talc filing in late 2024, attempting to carve out a “full pay” exception. The company argued that because it proposed to pay claimants the “full value” of their claims (as determined by the company), the Purdue restrictions should not apply. Judge Christopher Lopez rejected this interpretation in his March 31, 2025 dismissal, ruling that the plan contained impermissible non-consensual releases that violated the Supreme Court’s mandate.

The Ending Corporate Bankruptcy Abuse Act

While the courts addressed the interpretation of existing law, federal legislators moved to codify the prohibition against the Texas Two-Step. On July 23, 2024, Senators Sheldon Whitehouse (D-RI) and Josh Hawley (R-MO), alongside Representatives Emilia Sykes (D-OH) and Lance Gooden (R-TX), introduced the Ending Corporate Bankruptcy Abuse Act. This bipartisan legislation targeted the specific method Johnson & Johnson used to separate its assets from its liabilities.

The Act proposed two fundamental changes to the bankruptcy system:

• Presumption of Bad Faith: Courts would be instructed to presume that a Chapter 11 filing is in bad faith if the debtor was formed through a divisional merger (the “Two-Step”) within the preceding four years. This shifts the load of proof to the corporation to demonstrate a valid reorganizational purpose beyond litigation avoidance.
• Prohibition of Litigation Stays: The bill would prevent bankruptcy courts from issuing stays that halt litigation against non-bankrupt affiliates. This provision directly attacks the primary incentive for the Two-Step: the ability of a parent company to stop thousands of lawsuits without subjecting its own assets to bankruptcy court oversight.

“The Texas Two-Step has mired tens of thousands of injured Americans in protracted proceedings, while the mega-corporations that harmed them continue making money and avoiding penalties. Our bipartisan bill would end abuse of the bankruptcy process to ensure that victims get the day in court that our constitution entitles them to.”
, Senator Sheldon Whitehouse, July 23, 2024

Senate Judiciary Oversight

Senator Dick Durbin (D-IL), Chair of the Senate Judiciary Committee, maintained sustained pressure on Johnson & Johnson throughout 2024 and 2025. Following the Purdue ruling, the Committee held hearings to examine how major corporations continued to exploit bankruptcy venues, specifically the Southern District of Texas, to evade the Supreme Court’s intent. Durbin characterized the Red River Talc filing as a “manipulation” of the justice system, noting that J&J remained a highly profitable entity with a market capitalization exceeding $350 billion, far removed from the “financial distress” required for legitimate bankruptcy protection.

The Committee’s scrutiny focused on the between the company’s financial health and its legal maneuvering. During the “Evading Accountability” hearings, lawmakers highlighted that while J&J’s subsidiary claimed insolvency, the parent company continued to pay billions in dividends to shareholders. This “two-tiered justice system,” as described by Durbin, became a central theme in the legislative push to pass the Ending Corporate Bankruptcy Abuse Act.

Lobbying Expenditures and Corporate Defense

Johnson & Johnson responded to this legislative threat with a massive increase in federal lobbying expenditures. In the quarter of 2025 alone, the company spent $3. 34 million on lobbying activities, a 120% increase compared to the previous quarter. While the company’s disclosures “drug pricing” and “patent legislation” as key problem, the timing coincided precisely with the confirmation hearings for the Red River Talc bankruptcy and the reintroduction of bankruptcy reform bills.

Table 1: Johnson & Johnson Federal Lobbying Expenditures (Selected Quarters)

Quarter	Amount Spent	% Change (QoQ)	Key Legislative Context
Q4 2024	$1. 52 Million	,	Red River Talc Filing Preparation
Q1 2025	$3. 34 Million	+119. 7%	Red River Confirmation Hearings; ECBA Act Push
Q2 2025	$2. 10 Million	-37. 1%	Post-Dismissal Strategy Formulation

The aggressive spending reflected the high involved. A legislative ban on the Texas Two-Step would not only force J&J back into the tort system for talc claims would also eliminate a preferred liability management tool for other multinational corporations facing mass torts. The Chamber of Commerce and other business groups joined the opposition, arguing that the proposed laws would stifle legitimate corporate restructuring. Yet, the bipartisan nature of the ECBA, uniting progressive Democrats like Whitehouse with conservative Republicans like Hawley, suggested a broad consensus that the bankruptcy code required immediate reform to prevent future abuses.

The “Full Pay” Fallacy

A serious component of the legislative inquiry involved debunking the “full pay” narrative promoted by J&J. The company argued that its bankruptcy plan offered a more and equitable distribution of funds than the tort system. Legislators and legal experts countered that the bankruptcy process stripped plaintiffs of their Seventh Amendment right to a trial by jury. The dismissal of the Red River case validated this concern; Judge Lopez found that the voting process used to solicit support for the plan was fundamentally flawed, with tens of thousands of claimants given unreasonably short windows to vote, disenfranchising them.

By February 2026, the failure of the third bankruptcy and the looming threat of the Ending Corporate Bankruptcy Abuse Act had fundamentally altered the strategic calculus. The legislative branch, fortified by the Supreme Court’s Purdue decision, had encircled the “Two-Step” maneuver, leaving Johnson & Johnson with dwindling options outside of a detailed settlement negotiated directly within the multidistrict litigation.

SECTION 20: Official Committee of Talc Claimants Strategy: Rejection of Pre-Packaged Deals

the “Supermajority” Facade

The collapse of Johnson & Johnson’s third bankruptcy attempt in March 2025 was not a passive judicial occurrence the result of a forensic counter-operation by the Official Committee of Talc Claimants (TCC). Facing a “pre-packaged” Chapter 11 deal valued at approximately $9 billion, the TCC executed a strategy focused on invalidating the metrics J&J used to claim consensus. J&J asserted that 83% of claimants supported the plan, surpassing the 75% statutory threshold required for a cram-down under Section 524(g) of the Bankruptcy Code. The TCC’s investigation, yet, exposed widespread manipulation in the solicitation process, which Judge Christopher Lopez as a primary cause for dismissal.

The TCC’s legal team, including prominent figures such as Mike Papantonio and Andy Birchfield, dismantled the vote count by identifying “ballot stuffing” method. They presented evidence that J&J’s solicitation agent had accepted thousands of votes from claimants with unverified injuries or those represented by counsel who had not authorized the vote. In a decisive finding, Judge Lopez noted that while over 90, 000 votes were cast, “at least half of them cannot count” due to fatal irregularities, including an unreasonably short voting window that disenfranchised thousands of legitimate plaintiffs.

The “Vote No” Campaign and Valuation Disputes

Throughout late 2024 and early 2025, the TCC coordinated a “Vote No” campaign to unify plaintiff groups against the settlement. The core of their argument was financial: the $9 billion offer, when distributed across nearly 100, 000 claimants, would result in an average payout of approximately $120, 000 for ovarian cancer cases. The TCC contrasted this figure with the actuarial reality of the tort system, where individual verdicts frequently exceed $50 million. This valuation gap became the TCC’s primary weapon in persuading undecided firms to reject the deal.

The committee’s valuation strategy was vindicated in the months following the dismissal. The TCC pointed to the December 2025 Baltimore verdict of $1. 5 billion for a single plaintiff as proof that the bankruptcy offer represented less than 1% of the liability’s true market value. By anchoring their rejection in these hard metrics, the TCC successfully argued that the bankruptcy was not a reorganization effort a “cap and release” tactic designed to strip claimants of their Seventh Amendment right to a jury trial.

Legal Maneuver: The “Full Pay” Trap

A serious component of the TCC’s defense involved countering J&J’s “full pay” narrative. J&J argued that because the settlement amount was historically high, it constituted a “full payment” of valid claims, so bypassing the strict insolvency requirements of Chapter 11. The TCC leveraged the Supreme Court’s 2024 decision in Harrington v. Purdue Pharma, which restricted non-consensual third-party releases. The committee argued that J&J’s plan attempted to grant immunity to a solvent parent company without the genuine consent of the victims, a direct violation of the Purdue standard.

The TCC also attacked the “Texas Two-Step” method itself, arguing that Red River Talc LLC had no legitimate business purpose other than to serve as a liability dump. By demonstrating that the subsidiary had no operations, employees, or independent revenue, the TCC convinced the court that the filing absence the “valid reorganizational purpose” required by the Bankruptcy Code. This argument forced the dismissal on March 31, 2025, closing the door on J&J’s bankruptcy strategy for the immediate future.

Counter-Offensive: Disqualification and Ethics Battles

Following the dismissal, the conflict shifted to aggressive procedural warfare. In February 2026, J&J successfully moved to disqualify the Beasley Allen law firm from thousands of state court cases in New Jersey. The company alleged that the firm had improperly collaborated with a former J&J defense attorney to engineer a settlement strategy. While this disqualified the firm from specific state venues, the TCC maintained its leadership structure in the federal MDL. This development signaled a shift in J&J’s strategy from shared resolution to targeting the plaintiff leadership directly, a move the TCC characterized as an attempt to “decapitate” the opposition before the resumption of bellwether trials.

TCC vs. J&J: Valuation and Vote Metrics (2025-2026)

Metric	Johnson & Johnson Claim	TCC / Court Finding
Claimant Support	83% of votes cast	< 50% valid votes (Vote Certification Denied)
Settlement Offer	$9 Billion (Total Trust)	Rejected as “De Minimis” (Avg. $120k/claim)
Vote Count	93, 000+ Ballots	~45, 000 Invalidated due to irregularities
Financial Status	“Full Pay” Scenario	Solvent Parent / Bad Faith Filing
Benchmark Verdict	$18. 8 Million (Avg. Defense Est.)	$1. 5 Billion (Dec 2025 Actual Verdict)

Current Posture: February 2026

As of February 24, 2026, the TCC’s strategy has pivoted to maximizing pressure through the reactivated MDL 2738. With the bankruptcy stay lifted, the committee is pushing for an accelerated trial schedule under Judge Michael Shipp. The TCC has explicitly stated that no further settlement talks be entertained until J&J acknowledges the “post-dismissal premium”, a higher valuation baseline established by the recent billion-dollar verdicts. The committee’s unity remains tested by J&J’s disqualification tactics, the rejection of the $9 billion pre-pack remains the defining victory that forced the pharmaceutical giant back into the tort system.

The Solvency Paradox: A Under Siege

The dismissal of the Red River Talc bankruptcy in March 2025 and the subsequent reactivation of MDL 2738 have stripped Johnson & Johnson of its primary liability shield, exposing the healthcare giant’s balance sheet to the raw volatility of the tort system. The central tension of the 2025-2026 litigation phase is a financial paradox: J&J is too solvent to qualify for bankruptcy protection, yet faces an aggregate liability exposure that threatens to consume its free cash flow for the decade.

Judicial findings from the March 31, 2025, dismissal by Judge Christopher Lopez underscored that J&J’s ” balance sheet” was the very instrument that disqualified it from Chapter 11 relief. Unlike companies facing genuine insolvency, J&J’s liquidity metrics demonstrate a capacity to satisfy judgments, a fact that plaintiffs are leveraging to demand settlement values far exceeding the rejected $8 billion proposal.

Liquidity Analysis: The ” ” Metrics (2024-2025)

Financial disclosures from Q4 2025 reveal a corporation with immense, though slightly contracting, liquidity. As of December 31, 2025, J&J reported approximately $20. 1 billion in cash and marketable securities. While this represents a contraction from the $24. 5 billion reported at the end of 2024, the decline is largely attributable to aggressive stock buybacks and the continued servicing of legal defense costs, which exceeded $3 billion annually during the bankruptcy attempts.

The company’s ability to generate cash remains its most formidable defense, and its greatest liability in settlement negotiations.

Table 1: Johnson & Johnson Liquidity & Cash Flow (2023-2025)

Metric	FY 2023 (Actual)	FY 2024 (Actual)	FY 2025 (Preliminary)	YoY Change (’24-’25)
Cash & Marketable Securities	$22. 93 Billion	$24. 52 Billion	$20. 10 Billion	-18. 0%
Free Cash Flow (FCF)	$18. 61 Billion	$20. 52 Billion	$19. 70 Billion	-4. 0%
Legal Defense Spend (Est.)	$2. 1 Billion	$2. 8 Billion	$3. 4 Billion	+21. 4%
Net Debt Position	$29. 3 Billion	$36. 6 Billion	$45. 8 Billion	+25. 1%

“The debtor is not in financial distress. With over $20 billion in liquid assets and an AAA credit rating, the company possesses the operational capacity to address these claims in the tort system, yet painful that process may be.”
, Excerpt from Judge Christopher Lopez’s Dismissal Opinion, March 31, 2025.

Aggregate Liability Projections: The “Cherie Craft” Multiplier

The rejection of the $8. 2 billion settlement offer in 2025 has forced analysts to recalibrate liability models based on recent jury verdicts rather than bankruptcy trust matrices. The December 2025 Cherie Craft verdict in Baltimore, which awarded $1. 56 billion to a single plaintiff, has fundamentally broken the previous actuarial models used by J&J’s defense team.

Prior to the MDL reactivation, defense models assumed an average settlement value of approximately $120, 000 to $150, 000 per case, totaling roughly $8-10 billion for the 67, 622 pending actions. The post-dismissal reality is clear different. Plaintiff steering committees are targeting an average per-case value closer to $250, 000, with premium cases (mesothelioma and younger ovarian cancer plaintiffs) commanding significantly higher demands.

If the Craft verdict survives appeal even at a reduced amount, it establishes a “floor” for severe cases that renders the previous $8 billion cap obsolete. Financial analysts at Bloomberg Intelligence and Moody’s have revised their “worst-case” liability scenarios upward.

Scenario Analysis: Settlement vs. Litigation

The between J&J’s reserved funds and chance exposure creates a solvency gap that, while not existential, threatens shareholder returns and credit standing.

• Scenario A: Revised Global Settlement ($12-14 Billion). To halt the MDL fan-out, J&J may need to increase its offer by 50%. This would consume nearly 70% of FY 2025 Free Cash Flow would preserve the dividend and AAA rating.
• Scenario B: The “Bleed” Strategy ($10 Billion + Annual Defense). J&J continues to litigate individual cases, paying judgments as they arise. While this spreads the cost over years, the Craft verdict ($1. 5B) and the October 2025 Los Angeles verdict ($966M) demonstrate that of losses can equal the cost of a global settlement.
• Scenario C: Catastrophic Verdict Cascade (>$20 Billion). If the 2026 bellwether trials in MDL 2738 replicate the Baltimore results, aggregate liability could exceed J&J’s cash on hand, forcing debt issuance or asset liquidation.

Credit Ratings and the “AAA” Premium

even with the litigation headwinds, J&J remains one of only two U. S. companies with a Prime-1/AAA credit rating from Moody’s and S&P. yet, the outlook has darkened. In April 2025, following the bankruptcy dismissal, Moody’s noted that while J&J’s business profile is “strong,” the “uncapped nature of tort liability” introduces a new risk factor.

The company’s debt-to-EBITDA ratio remains conservative, 1. 5x, the rapid accumulation of debt, rising from $29. 3 billion in 2023 to $45. 8 billion in 2025, signals that J&J is leveraging its balance sheet to maintain liquidity amidst the legal storm. The preservation of the AAA rating is directly linked to the containment of the talc liability. A settlement exceeding $15 billion, or a sustained run of billion-dollar verdicts, could trigger a historic downgrade, raising the cost of capital for future acquisitions.

Market Reaction: The Valuation Discount

Equity markets have priced in a “litigation discount” on J&J stock. Throughout late 2025, J&J shares underperformed the S&P Healthcare index, trading at a P/E multiple compression compared to peers like Merck or AbbVie. Investors are treating the talc liability as an uncapped variable debt, penalizing the stock price until a final number is fixed. The $1. 5 billion Craft verdict caused a 0. 8% drop in share price, a muted reaction that suggests the market has already braced for high-value losses, yet the cumulative effect of these judgments the “safe haven” status the stock once held.

, the solvency metrics confirm that Johnson & Johnson can pay. The question for 2026 is no longer about bankruptcy, about how much of the company’s future earnings be diverted from R&D and dividends to satisfy a liability that the courts have refused to contain.

The “Wolfson Report” and the April 2026 Daubert Showdown

The reactivation of MDL 2738 has accelerated into a serious evidentiary phase following the January 22, 2026, findings by Special Master Freda Wolfson. Wolfson, the retired U. S. District Judge who previously presided over the litigation, issued a detailed report recommending the admission of plaintiff expert testimony linking cosmetic talc to ovarian cancer. This recommendation directly contradicts Johnson & Johnson’s long-standing assertion that the science underlying these claims is “junk” and inadmissible under Federal Rule of Evidence 702.

Judge Michael Shipp has established a rigid scheduling order for the second quarter of 2026 to address these findings. Defense counsel must file objections to the Wolfson Report by March 15, 2026. Plaintiffs are required to respond by April 10, 2026. A final Daubert hearing is docketed for May 4, 2026, in Trenton, New Jersey. Legal analysts anticipate that Judge Shipp’s ruling on this matter determine the viability of over 58, 000 pending federal cases. A ruling affirming Wolfson’s recommendations would strip Johnson & Johnson of its primary defense shield and clear the route for a new wave of federal bellwether trials by late 2026.

Mediation Standoff: The “Kurdi Protocol” vs. Verdict Reality

Parallel to the evidentiary battles, court-ordered mediation remains in a volatile stalemate. Fouad Kurdi, appointed as the settlement mediator in July 2025, has struggled to the valuation gap between the opposing parties. The “Kurdi Protocol,” established in September 2025 to structure global settlement talks, faces severe following the catastrophic verdicts of late 2025. The plaintiffs’ negotiation committee has reportedly hardened its demand floor, citing the $1. 5 billion Cherie Craft verdict in Baltimore as a new baseline for punitive liability.

Johnson & Johnson continues to resist a global resolution at the plaintiffs’ current price point. The company’s strategy relies on the appellate process to overturn the Craft judgment and other recent losses. yet, the sheer volume of adverse rulings has weakened their use in the mediation room. Sources close to the negotiations indicate that the company may be forced to revise its settlement offer, previously capped at $8 billion in the failed Red River Talc bankruptcy, to a figure exceeding $12 billion to halt the litigation momentum.

Q4 2025, Q1 2026: Key Verdicts Driving Mediation use

Date	Jurisdiction	Plaintiff	Verdict Amount	Key Finding
Dec 22, 2025	Baltimore City, MD	Cherie Craft	$1. 56 Billion	Punitive damages for failure to warn of asbestos.
Dec 12, 2025	Los Angeles, CA	Kent / Schultz	$40 Million	Ovarian cancer link confirmed by jury.
Dec 19, 2025	Ramsey County, MN	Pleural Meso. Case	$65. 5 Million	Rejection of “safe talc” defense.
Feb 16, 2026	Philadelphia, PA	Ovarian Case	$250, 000	Liability found even with lower damages.

Remand Wave and State Court Pressure

The failure of the Red River Talc bankruptcy has also triggered a procedural method known as the “remand wave.” Judge Shipp has indicated he begin remanding cases to their original state courts if the federal bellwether process stalls. This threat places additional pressure on Johnson & Johnson, as state courts in California, Missouri, and Pennsylvania move faster than the federal MDL. The prospect of fighting dozens of simultaneous state trials in Q3 and Q4 2026 serves as a catalyst for the company to engage more seriously in the Kurdi-led mediation.

“The math has changed. In 2024, the company faced a theoretical liability. In 2026, they face a verified ledger of ten-figure verdicts and a federal docket that is no longer frozen. The cost of delay is daily.”
, Legal Analysis from the February 2026 MDL Status Conference

Financial of the Evidentiary Timeline

The convergence of the Q2 2026 Daubert deadlines and the stalling mediation has created a binary financial risk for Johnson & Johnson. If Judge Shipp admits the expert testimony in May, the company’s stock could face renewed volatility similar to the drops seen after the 2018 Ingham verdict. Conversely, a successful exclusion of the experts would decimate the plaintiffs’ use and likely force a settlement at a lower valuation. Investors and officials are closely monitoring the docket for the weeks of April 10 and May 4, 2026, marking them as the most significant dates in the litigation’s decade-long history.